Unacceptable principal diagnosis - ICD-10-CM Medicare Code Edits

Streptococcus, Staphylococcus, and Enterococcus as the cause of diseases classified elsewhere (B95)

• B95.0 - Streptococcus, group A, as the cause of diseases classified elsewhere

• B95.1 - Streptococcus, group B, as the cause of diseases classified elsewhere

• B95.2 - Enterococcus as the cause of diseases classified elsewhere

• B95.3 - Streptococcus pneumoniae as the cause of diseases classified elsewhere

• B95.4 - Other streptococcus as the cause of diseases classified elsewhere

• B95.5 - Unspecified streptococcus as the cause of diseases classified elsewhere

• B95.61 - Methicillin susceptible Staphylococcus aureus infection as the cause of diseases classified elsewhere

• B95.62 - Methicillin resistant Staphylococcus aureus infection as the cause of diseases classified elsewhere

• B95.7 - Other staphylococcus as the cause of diseases classified elsewhere

• B95.8 - Unspecified staphylococcus as the cause of diseases classified elsewhere

Other bacterial agents as the cause of diseases classified elsewhere (B96)

• B96.0 - Mycoplasma pneumoniae [M. pneumoniae] as the cause of diseases classified elsewhere

• B96.1 - Klebsiella pneumoniae [K. pneumoniae] as the cause of diseases classified elsewhere

• B96.20 - Unspecified Escherichia coli [E. coli] as the cause of diseases classified elsewhere

• B96.21 - Shiga toxin-producing Escherichia coli [E. coli] [STEC] O157 as the cause of diseases classified elsewhere

• B96.22 - Other specified Shiga toxin-producing Escherichia coli [E. coli] [STEC] as the cause of diseases classified elsewhere

• B96.23 - Unspecified Shiga toxin-producing Escherichia coli [E. coli] [STEC] as the cause of diseases classified elsewhere

• B96.29 - Other Escherichia coli [E. coli] as the cause of diseases classified elsewhere

• B96.3 - Hemophilus influenzae [H. influenzae] as the cause of diseases classified elsewhere

• B96.4 - Proteus (mirabilis) (morganii) as the cause of diseases classified elsewhere

• B96.5 - Pseudomonas (aeruginosa) (mallei) (pseudomallei) as the cause of diseases classified elsewhere

• B96.6 - Bacteroides fragilis [B. fragilis] as the cause of diseases classified elsewhere

• B96.7 - Clostridium perfringens [C. perfringens] as the cause of diseases classified elsewhere

• B96.81 - Helicobacter pylori [H. pylori] as the cause of diseases classified elsewhere

• B96.82 - Vibrio vulnificus as the cause of diseases classified elsewhere

• B96.83 - Acinetobacter baumannii as the cause of diseases classified elsewhere

• B96.89 - Other specified bacterial agents as the cause of diseases classified elsewhere

Viral agents as the cause of diseases classified elsewhere (B97)

• B97.0 - Adenovirus as the cause of diseases classified elsewhere

• B97.10 - Unspecified enterovirus as the cause of diseases classified elsewhere

• B97.11 - Coxsackievirus as the cause of diseases classified elsewhere

• B97.12 - Echovirus as the cause of diseases classified elsewhere

• B97.19 - Other enterovirus as the cause of diseases classified elsewhere

• B97.21 - SARS-associated coronavirus as the cause of diseases classified elsewhere

• B97.29 - Other coronavirus as the cause of diseases classified elsewhere

• B97.30 - Unspecified retrovirus as the cause of diseases classified elsewhere

• B97.31 - Lentivirus as the cause of diseases classified elsewhere

• B97.32 - Oncovirus as the cause of diseases classified elsewhere

• B97.33 - Human T-cell lymphotrophic virus, type I [HTLV-I] as the cause of diseases classified elsewhere

• B97.34 - Human T-cell lymphotrophic virus, type II [HTLV-II] as the cause of diseases classified elsewhere

• B97.35 - Human immunodeficiency virus, type 2 [HIV 2] as the cause of diseases classified elsewhere

• B97.39 - Other retrovirus as the cause of diseases classified elsewhere

• B97.4 - Respiratory syncytial virus as the cause of diseases classified elsewhere

• B97.5 - Reovirus as the cause of diseases classified elsewhere

• B97.6 - Parvovirus as the cause of diseases classified elsewhere

• B97.7 - Papillomavirus as the cause of diseases classified elsewhere

• B97.81 - Human metapneumovirus as the cause of diseases classified elsewhere

• B97.89 - Other viral agents as the cause of diseases classified elsewhere

Malignant neoplasm without specification of site (C80)

• C80.2 - Malignant neoplasm associated with transplanted organ

Other neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue (D47)

• D47.Z1 - Post-transplant lymphoproliferative disorder (PTLD)

Other disorders involving the immune mechanism, not elsewhere classified (D89)

• D89.810 - Acute graft-versus-host disease

• D89.811 - Chronic graft-versus-host disease

• D89.812 - Acute on chronic graft-versus-host disease

• D89.813 - Graft-versus-host disease, unspecified

• D89.831 - Cytokine release syndrome, grade 1

• D89.832 - Cytokine release syndrome, grade 2

• D89.833 - Cytokine release syndrome, grade 3

• D89.834 - Cytokine release syndrome, grade 4

• D89.835 - Cytokine release syndrome, grade 5

• D89.839 - Cytokine release syndrome, grade unspecified

Other and unspecified metabolic disorders (E88)

• E88.A - Wasting disease (syndrome) due to underlying condition

Delirium due to known physiological condition (F05)

• F05 - Delirium due to known physiological condition

Other mental disorders due to known physiological condition (F06)

• F06.70 - Mild neurocognitive disorder due to known physiological condition without behavioral disturbance

• F06.71 - Mild neurocognitive disorder due to known physiological condition with behavioral disturbance

Personality and behavioral disorders due to known physiological condition (F07)

• F07.89 - Other personality and behavioral disorders due to known physiological condition

Nicotine dependence (F17)

• F17.200 - Nicotine dependence, unspecified, uncomplicated

• F17.201 - Nicotine dependence, unspecified, in remission

• F17.210 - Nicotine dependence, cigarettes, uncomplicated

• F17.211 - Nicotine dependence, cigarettes, in remission

• F17.220 - Nicotine dependence, chewing tobacco, uncomplicated

• F17.221 - Nicotine dependence, chewing tobacco, in remission

• F17.290 - Nicotine dependence, other tobacco product, uncomplicated

• F17.291 - Nicotine dependence, other tobacco product, in remission

Sexual dysfunction not due to a substance or known physiological condition (F52)

• F52.9 - Unspecified sexual dysfunction not due to a substance or known physiological condition

Specific developmental disorders of scholastic skills (F81)

• F81.9 - Developmental disorder of scholastic skills, unspecified

Disorders of myoneural junction and muscle in diseases classified elsewhere (G73)

• G73.1 - Lambert-Eaton syndrome in neoplastic disease

Toxic encephalopathy (G92)

• G92.00 - Immune effector cell-associated neurotoxicity syndrome, grade unspecified

• G92.01 - Immune effector cell-associated neurotoxicity syndrome, grade 1

• G92.02 - Immune effector cell-associated neurotoxicity syndrome, grade 2

• G92.03 - Immune effector cell-associated neurotoxicity syndrome, grade 3

• G92.04 - Immune effector cell-associated neurotoxicity syndrome, grade 4

• G92.05 - Immune effector cell-associated neurotoxicity syndrome, grade 5

Keratitis (H16)

• H16.8 - Other keratitis

Retinal disorders in diseases classified elsewhere (H36)

• H36.811 - Nonproliferative sickle-cell retinopathy, right eye

• H36.812 - Nonproliferative sickle-cell retinopathy, left eye

• H36.813 - Nonproliferative sickle-cell retinopathy, bilateral

• H36.819 - Nonproliferative sickle-cell retinopathy, unspecified eye

• H36.821 - Proliferative sickle-cell retinopathy, right eye

• H36.822 - Proliferative sickle-cell retinopathy, left eye

• H36.823 - Proliferative sickle-cell retinopathy, bilateral

• H36.829 - Proliferative sickle-cell retinopathy, unspecified eye

Glaucoma (H40)

• H40.1210 - Low-tension glaucoma, right eye, stage unspecified

• H40.1211 - Low-tension glaucoma, right eye, mild stage

• H40.1212 - Low-tension glaucoma, right eye, moderate stage

• H40.1213 - Low-tension glaucoma, right eye, severe stage

• H40.1214 - Low-tension glaucoma, right eye, indeterminate stage

• H40.1220 - Low-tension glaucoma, left eye, stage unspecified

• H40.1221 - Low-tension glaucoma, left eye, mild stage

• H40.1222 - Low-tension glaucoma, left eye, moderate stage

• H40.1223 - Low-tension glaucoma, left eye, severe stage

• H40.1224 - Low-tension glaucoma, left eye, indeterminate stage

• H40.1230 - Low-tension glaucoma, bilateral, stage unspecified

• H40.1231 - Low-tension glaucoma, bilateral, mild stage

• H40.1232 - Low-tension glaucoma, bilateral, moderate stage

• H40.1233 - Low-tension glaucoma, bilateral, severe stage

• H40.1234 - Low-tension glaucoma, bilateral, indeterminate stage

• H40.1290 - Low-tension glaucoma, unspecified eye, stage unspecified

• H40.1291 - Low-tension glaucoma, unspecified eye, mild stage

• H40.1292 - Low-tension glaucoma, unspecified eye, moderate stage

• H40.1293 - Low-tension glaucoma, unspecified eye, severe stage

• H40.1294 - Low-tension glaucoma, unspecified eye, indeterminate stage

• H40.1310 - Pigmentary glaucoma, right eye, stage unspecified

• H40.1311 - Pigmentary glaucoma, right eye, mild stage

• H40.1312 - Pigmentary glaucoma, right eye, moderate stage

• H40.1313 - Pigmentary glaucoma, right eye, severe stage

• H40.1314 - Pigmentary glaucoma, right eye, indeterminate stage

• H40.1320 - Pigmentary glaucoma, left eye, stage unspecified

• H40.1321 - Pigmentary glaucoma, left eye, mild stage

• H40.1322 - Pigmentary glaucoma, left eye, moderate stage

• H40.1323 - Pigmentary glaucoma, left eye, severe stage

• H40.1324 - Pigmentary glaucoma, left eye, indeterminate stage

• H40.1330 - Pigmentary glaucoma, bilateral, stage unspecified

• H40.1331 - Pigmentary glaucoma, bilateral, mild stage

• H40.1332 - Pigmentary glaucoma, bilateral, moderate stage

• H40.1333 - Pigmentary glaucoma, bilateral, severe stage

• H40.1334 - Pigmentary glaucoma, bilateral, indeterminate stage

• H40.1390 - Pigmentary glaucoma, unspecified eye, stage unspecified

• H40.1391 - Pigmentary glaucoma, unspecified eye, mild stage

• H40.1392 - Pigmentary glaucoma, unspecified eye, moderate stage

• H40.1393 - Pigmentary glaucoma, unspecified eye, severe stage

• H40.1394 - Pigmentary glaucoma, unspecified eye, indeterminate stage

• H40.151 - Residual stage of open-angle glaucoma, right eye

• H40.152 - Residual stage of open-angle glaucoma, left eye

• H40.153 - Residual stage of open-angle glaucoma, bilateral

• H40.159 - Residual stage of open-angle glaucoma, unspecified eye

Blindness and low vision (H54)

• H54.7 - Unspecified visual loss

Other disorders of eye and adnexa (H57)

• H57.9 - Unspecified disorder of eye and adnexa

Other disorders of ear, not elsewhere classified (H93)

• H93.90 - Unspecified disorder of ear, unspecified ear

• H93.91 - Unspecified disorder of right ear

• H93.92 - Unspecified disorder of left ear

• H93.93 - Unspecified disorder of ear, bilateral

Chronic ischemic heart disease (I25)

• I25.82 - Chronic total occlusion of coronary artery

• I25.83 - Coronary atherosclerosis due to lipid rich plaque

• I25.84 - Coronary atherosclerosis due to calcified coronary lesion

Pulmonary embolism (I26)

• I26.01 - Septic pulmonary embolism with acute cor pulmonale

• I26.03 - Cement embolism of pulmonary artery with acute cor pulmonale

• I26.90 - Septic pulmonary embolism without acute cor pulmonale

• I26.95 - Cement embolism of pulmonary artery without acute cor pulmonale

Other diseases of pericardium (I31)

• I31.4 - Cardiac tamponade

Cardiac arrest (I46)

• I46.2 - Cardiac arrest due to underlying cardiac condition

• I46.8 - Cardiac arrest due to other underlying condition

Atherosclerosis (I70)

• I70.92 - Chronic total occlusion of artery of the extremities

Septic arterial embolism (I76)

• I76 - Septic arterial embolism

Viral pneumonia, not elsewhere classified (J12)

• J12.82 - Pneumonia due to coronavirus disease 2019

Other and unspecified disorders of nose and nasal sinuses (J34)

• J34.8200 - Internal nasal valve collapse, unspecified

• J34.8201 - Internal nasal valve collapse, static

• J34.8202 - Internal nasal valve collapse, dynamic

• J34.8210 - External nasal valve collapse, unspecified

• J34.8211 - External nasal valve collapse, static

• J34.8212 - External nasal valve collapse, dynamic

• J34.829 - Nasal valve collapse, unspecified

Pneumothorax and air leak (J93)

• J93.12 - Secondary spontaneous pneumothorax

Fibrosis and cirrhosis of liver (K74)

• K74.00 - Hepatic fibrosis, unspecified

• K74.01 - Hepatic fibrosis, early fibrosis

• K74.02 - Hepatic fibrosis, advanced fibrosis

Other diseases of liver (K76)

• K76.81 - Hepatopulmonary syndrome

Exfoliation due to erythematous conditions according to extent of body surface involved (L49)

• L49.0 - Exfoliation due to erythematous condition involving less than 10 percent of body surface

• L49.1 - Exfoliation due to erythematous condition involving 10-19 percent of body surface

• L49.2 - Exfoliation due to erythematous condition involving 20-29 percent of body surface

• L49.3 - Exfoliation due to erythematous condition involving 30-39 percent of body surface

• L49.4 - Exfoliation due to erythematous condition involving 40-49 percent of body surface

• L49.5 - Exfoliation due to erythematous condition involving 50-59 percent of body surface

• L49.6 - Exfoliation due to erythematous condition involving 60-69 percent of body surface

• L49.7 - Exfoliation due to erythematous condition involving 70-79 percent of body surface

• L49.8 - Exfoliation due to erythematous condition involving 80-89 percent of body surface

• L49.9 - Exfoliation due to erythematous condition involving 90 or more percent of body surface

Kyphosis and lordosis (M40)

• M40.10 - Other secondary kyphosis, site unspecified

• M40.12 - Other secondary kyphosis, cervical region

• M40.13 - Other secondary kyphosis, cervicothoracic region

• M40.14 - Other secondary kyphosis, thoracic region

• M40.15 - Other secondary kyphosis, thoracolumbar region

Scoliosis (M41)

• M41.50 - Other secondary scoliosis, site unspecified

• M41.52 - Other secondary scoliosis, cervical region

• M41.53 - Other secondary scoliosis, cervicothoracic region

• M41.54 - Other secondary scoliosis, thoracic region

• M41.55 - Other secondary scoliosis, thoracolumbar region

• M41.56 - Other secondary scoliosis, lumbar region

• M41.57 - Other secondary scoliosis, lumbosacral region

Other disorders of breast (N64)

• N64.1 - Fat necrosis of breast

Supervision of high risk pregnancy (O09)

• O09.00 - Supervision of pregnancy with history of infertility, unspecified trimester

• O09.01 - Supervision of pregnancy with history of infertility, first trimester

• O09.02 - Supervision of pregnancy with history of infertility, second trimester

• O09.03 - Supervision of pregnancy with history of infertility, third trimester

• O09.10 - Supervision of pregnancy with history of ectopic pregnancy, unspecified trimester

• O09.11 - Supervision of pregnancy with history of ectopic pregnancy, first trimester

• O09.12 - Supervision of pregnancy with history of ectopic pregnancy, second trimester

• O09.13 - Supervision of pregnancy with history of ectopic pregnancy, third trimester

• O09.211 - Supervision of pregnancy with history of pre-term labor, first trimester

• O09.212 - Supervision of pregnancy with history of pre-term labor, second trimester

• O09.213 - Supervision of pregnancy with history of pre-term labor, third trimester

• O09.219 - Supervision of pregnancy with history of pre-term labor, unspecified trimester

• O09.291 - Supervision of pregnancy with other poor reproductive or obstetric history, first trimester

• O09.292 - Supervision of pregnancy with other poor reproductive or obstetric history, second trimester

• O09.293 - Supervision of pregnancy with other poor reproductive or obstetric history, third trimester

• O09.299 - Supervision of pregnancy with other poor reproductive or obstetric history, unspecified trimester

• O09.30 - Supervision of pregnancy with insufficient antenatal care, unspecified trimester

• O09.31 - Supervision of pregnancy with insufficient antenatal care, first trimester

• O09.32 - Supervision of pregnancy with insufficient antenatal care, second trimester

• O09.33 - Supervision of pregnancy with insufficient antenatal care, third trimester

• O09.40 - Supervision of pregnancy with grand multiparity, unspecified trimester

• O09.41 - Supervision of pregnancy with grand multiparity, first trimester

• O09.42 - Supervision of pregnancy with grand multiparity, second trimester

• O09.43 - Supervision of pregnancy with grand multiparity, third trimester

• O09.511 - Supervision of elderly primigravida, first trimester

• O09.512 - Supervision of elderly primigravida, second trimester

• O09.513 - Supervision of elderly primigravida, third trimester

• O09.519 - Supervision of elderly primigravida, unspecified trimester

• O09.521 - Supervision of elderly multigravida, first trimester

• O09.522 - Supervision of elderly multigravida, second trimester

• O09.523 - Supervision of elderly multigravida, third trimester

• O09.529 - Supervision of elderly multigravida, unspecified trimester

• O09.611 - Supervision of young primigravida, first trimester

• O09.612 - Supervision of young primigravida, second trimester

• O09.613 - Supervision of young primigravida, third trimester

• O09.619 - Supervision of young primigravida, unspecified trimester

• O09.621 - Supervision of young multigravida, first trimester

• O09.622 - Supervision of young multigravida, second trimester

• O09.623 - Supervision of young multigravida, third trimester

• O09.629 - Supervision of young multigravida, unspecified trimester

• O09.70 - Supervision of high risk pregnancy due to social problems, unspecified trimester

• O09.71 - Supervision of high risk pregnancy due to social problems, first trimester

• O09.72 - Supervision of high risk pregnancy due to social problems, second trimester

• O09.73 - Supervision of high risk pregnancy due to social problems, third trimester

• O09.811 - Supervision of pregnancy resulting from assisted reproductive technology, first trimester

• O09.812 - Supervision of pregnancy resulting from assisted reproductive technology, second trimester

• O09.813 - Supervision of pregnancy resulting from assisted reproductive technology, third trimester

• O09.819 - Supervision of pregnancy resulting from assisted reproductive technology, unspecified trimester

• O09.821 - Supervision of pregnancy with history of in utero procedure during previous pregnancy, first trimester

• O09.822 - Supervision of pregnancy with history of in utero procedure during previous pregnancy, second trimester

• O09.823 - Supervision of pregnancy with history of in utero procedure during previous pregnancy, third trimester

• O09.829 - Supervision of pregnancy with history of in utero procedure during previous pregnancy, unspecified trimester

• O09.891 - Supervision of other high risk pregnancies, first trimester

• O09.892 - Supervision of other high risk pregnancies, second trimester

• O09.893 - Supervision of other high risk pregnancies, third trimester

• O09.899 - Supervision of other high risk pregnancies, unspecified trimester

• O09.90 - Supervision of high risk pregnancy, unspecified, unspecified trimester

• O09.91 - Supervision of high risk pregnancy, unspecified, first trimester

• O09.92 - Supervision of high risk pregnancy, unspecified, second trimester

• O09.93 - Supervision of high risk pregnancy, unspecified, third trimester

• O09.A0 - Supervision of pregnancy with history of molar pregnancy, unspecified trimester

• O09.A1 - Supervision of pregnancy with history of molar pregnancy, first trimester

• O09.A2 - Supervision of pregnancy with history of molar pregnancy, second trimester

• O09.A3 - Supervision of pregnancy with history of molar pregnancy, third trimester

Maternal care for other fetal problems (O36)

• O36.80X0 - Pregnancy with inconclusive fetal viability, not applicable or unspecified

• O36.80X1 - Pregnancy with inconclusive fetal viability, fetus 1

• O36.80X2 - Pregnancy with inconclusive fetal viability, fetus 2

• O36.80X3 - Pregnancy with inconclusive fetal viability, fetus 3

• O36.80X4 - Pregnancy with inconclusive fetal viability, fetus 4

• O36.80X5 - Pregnancy with inconclusive fetal viability, fetus 5

• O36.80X9 - Pregnancy with inconclusive fetal viability, other fetus

Sequelae of complication of pregnancy, childbirth, and the puerperium (O94)

• O94 - Sequelae of complication of pregnancy, childbirth, and the puerperium

Other maternal diseases classifiable elsewhere but complicating pregnancy, childbirth and the puerperium (O99)

• O99.820 - Streptococcus B carrier state complicating pregnancy

• O99.825 - Streptococcus B carrier state complicating the puerperium

Cough (R05)

• R05.4 - Cough syncope

Ascites (R18)

• R18.0 - Malignant ascites

Other symptoms and signs involving the nervous and musculoskeletal systems (R29)

• R29.700 - NIHSS score 0

• R29.701 - NIHSS score 1

• R29.702 - NIHSS score 2

• R29.703 - NIHSS score 3

• R29.704 - NIHSS score 4

• R29.705 - NIHSS score 5

• R29.706 - NIHSS score 6

• R29.707 - NIHSS score 7

• R29.708 - NIHSS score 8

• R29.709 - NIHSS score 9

• R29.710 - NIHSS score 10

• R29.711 - NIHSS score 11

• R29.712 - NIHSS score 12

• R29.713 - NIHSS score 13

• R29.714 - NIHSS score 14

• R29.715 - NIHSS score 15

• R29.716 - NIHSS score 16

• R29.717 - NIHSS score 17

• R29.718 - NIHSS score 18

• R29.719 - NIHSS score 19

• R29.720 - NIHSS score 20

• R29.721 - NIHSS score 21

• R29.722 - NIHSS score 22

• R29.723 - NIHSS score 23

• R29.724 - NIHSS score 24

• R29.725 - NIHSS score 25

• R29.726 - NIHSS score 26

• R29.727 - NIHSS score 27

• R29.728 - NIHSS score 28

• R29.729 - NIHSS score 29

• R29.730 - NIHSS score 30

• R29.731 - NIHSS score 31

• R29.732 - NIHSS score 32

• R29.733 - NIHSS score 33

• R29.734 - NIHSS score 34

• R29.735 - NIHSS score 35

• R29.736 - NIHSS score 36

• R29.737 - NIHSS score 37

• R29.738 - NIHSS score 38

• R29.739 - NIHSS score 39

• R29.740 - NIHSS score 40

• R29.741 - NIHSS score 41

• R29.742 - NIHSS score 42

Somnolence, stupor and coma (R40)

• R40.2110 - Coma scale, eyes open, never, unspecified time

• R40.2111 - Coma scale, eyes open, never, in the field [EMT or ambulance]

• R40.2112 - Coma scale, eyes open, never, at arrival to emergency department

• R40.2113 - Coma scale, eyes open, never, at hospital admission

• R40.2114 - Coma scale, eyes open, never, 24 hours or more after hospital admission

• R40.2120 - Coma scale, eyes open, to pain, unspecified time

• R40.2121 - Coma scale, eyes open, to pain, in the field [EMT or ambulance]

• R40.2122 - Coma scale, eyes open, to pain, at arrival to emergency department

• R40.2123 - Coma scale, eyes open, to pain, at hospital admission

• R40.2124 - Coma scale, eyes open, to pain, 24 hours or more after hospital admission

• R40.2130 - Coma scale, eyes open, to sound, unspecified time

• R40.2131 - Coma scale, eyes open, to sound, in the field [EMT or ambulance]

• R40.2132 - Coma scale, eyes open, to sound, at arrival to emergency department

• R40.2133 - Coma scale, eyes open, to sound, at hospital admission

• R40.2134 - Coma scale, eyes open, to sound, 24 hours or more after hospital admission

• R40.2140 - Coma scale, eyes open, spontaneous, unspecified time

• R40.2141 - Coma scale, eyes open, spontaneous, in the field [EMT or ambulance]

• R40.2142 - Coma scale, eyes open, spontaneous, at arrival to emergency department

• R40.2143 - Coma scale, eyes open, spontaneous, at hospital admission

• R40.2144 - Coma scale, eyes open, spontaneous, 24 hours or more after hospital admission

• R40.2210 - Coma scale, best verbal response, none, unspecified time

• R40.2211 - Coma scale, best verbal response, none, in the field [EMT or ambulance]

• R40.2212 - Coma scale, best verbal response, none, at arrival to emergency department

• R40.2213 - Coma scale, best verbal response, none, at hospital admission

• R40.2214 - Coma scale, best verbal response, none, 24 hours or more after hospital admission

• R40.2220 - Coma scale, best verbal response, incomprehensible words, unspecified time

• R40.2221 - Coma scale, best verbal response, incomprehensible words, in the field [EMT or ambulance]

• R40.2222 - Coma scale, best verbal response, incomprehensible words, at arrival to emergency department

• R40.2223 - Coma scale, best verbal response, incomprehensible words, at hospital admission

• R40.2224 - Coma scale, best verbal response, incomprehensible words, 24 hours or more after hospital admission

• R40.2230 - Coma scale, best verbal response, inappropriate words, unspecified time

• R40.2231 - Coma scale, best verbal response, inappropriate words, in the field [EMT or ambulance]

• R40.2232 - Coma scale, best verbal response, inappropriate words, at arrival to emergency department

• R40.2233 - Coma scale, best verbal response, inappropriate words, at hospital admission

• R40.2234 - Coma scale, best verbal response, inappropriate words, 24 hours or more after hospital admission

• R40.2240 - Coma scale, best verbal response, confused conversation, unspecified time

• R40.2241 - Coma scale, best verbal response, confused conversation, in the field [EMT or ambulance]

• R40.2242 - Coma scale, best verbal response, confused conversation, at arrival to emergency department

• R40.2243 - Coma scale, best verbal response, confused conversation, at hospital admission

• R40.2244 - Coma scale, best verbal response, confused conversation, 24 hours or more after hospital admission

• R40.2250 - Coma scale, best verbal response, oriented, unspecified time

• R40.2251 - Coma scale, best verbal response, oriented, in the field [EMT or ambulance]

• R40.2252 - Coma scale, best verbal response, oriented, at arrival to emergency department

• R40.2253 - Coma scale, best verbal response, oriented, at hospital admission

• R40.2254 - Coma scale, best verbal response, oriented, 24 hours or more after hospital admission

• R40.2310 - Coma scale, best motor response, none, unspecified time

• R40.2311 - Coma scale, best motor response, none, in the field [EMT or ambulance]

• R40.2312 - Coma scale, best motor response, none, at arrival to emergency department

• R40.2313 - Coma scale, best motor response, none, at hospital admission

• R40.2314 - Coma scale, best motor response, none, 24 hours or more after hospital admission

• R40.2320 - Coma scale, best motor response, extension, unspecified time

• R40.2321 - Coma scale, best motor response, extension, in the field [EMT or ambulance]

• R40.2322 - Coma scale, best motor response, extension, at arrival to emergency department

• R40.2323 - Coma scale, best motor response, extension, at hospital admission

• R40.2324 - Coma scale, best motor response, extension, 24 hours or more after hospital admission

• R40.2330 - Coma scale, best motor response, abnormal flexion, unspecified time

• R40.2331 - Coma scale, best motor response, abnormal flexion, in the field [EMT or ambulance]

• R40.2332 - Coma scale, best motor response, abnormal flexion, at arrival to emergency department

• R40.2333 - Coma scale, best motor response, abnormal flexion, at hospital admission

• R40.2334 - Coma scale, best motor response, abnormal flexion, 24 hours or more after hospital admission

• R40.2340 - Coma scale, best motor response, flexion withdrawal, unspecified time

• R40.2341 - Coma scale, best motor response, flexion withdrawal, in the field [EMT or ambulance]

• R40.2342 - Coma scale, best motor response, flexion withdrawal, at arrival to emergency department

• R40.2343 - Coma scale, best motor response, flexion withdrawal, at hospital admission

• R40.2344 - Coma scale, best motor response, flexion withdrawal, 24 hours or more after hospital admission

• R40.2350 - Coma scale, best motor response, localizes pain, unspecified time

• R40.2351 - Coma scale, best motor response, localizes pain, in the field [EMT or ambulance]

• R40.2352 - Coma scale, best motor response, localizes pain, at arrival to emergency department

• R40.2353 - Coma scale, best motor response, localizes pain, at hospital admission

• R40.2354 - Coma scale, best motor response, localizes pain, 24 hours or more after hospital admission

• R40.2360 - Coma scale, best motor response, obeys commands, unspecified time

• R40.2361 - Coma scale, best motor response, obeys commands, in the field [EMT or ambulance]

• R40.2362 - Coma scale, best motor response, obeys commands, at arrival to emergency department

• R40.2363 - Coma scale, best motor response, obeys commands, at hospital admission

• R40.2364 - Coma scale, best motor response, obeys commands, 24 hours or more after hospital admission

• R40.2410 - Glasgow coma scale score 13-15, unspecified time

• R40.2411 - Glasgow coma scale score 13-15, in the field [EMT or ambulance]

• R40.2412 - Glasgow coma scale score 13-15, at arrival to emergency department

• R40.2413 - Glasgow coma scale score 13-15, at hospital admission

• R40.2414 - Glasgow coma scale score 13-15, 24 hours or more after hospital admission

• R40.2420 - Glasgow coma scale score 9-12, unspecified time

• R40.2421 - Glasgow coma scale score 9-12, in the field [EMT or ambulance]

• R40.2422 - Glasgow coma scale score 9-12, at arrival to emergency department

• R40.2423 - Glasgow coma scale score 9-12, at hospital admission

• R40.2424 - Glasgow coma scale score 9-12, 24 hours or more after hospital admission

• R40.2430 - Glasgow coma scale score 3-8, unspecified time

• R40.2431 - Glasgow coma scale score 3-8, in the field [EMT or ambulance]

• R40.2432 - Glasgow coma scale score 3-8, at arrival to emergency department

• R40.2433 - Glasgow coma scale score 3-8, at hospital admission

• R40.2434 - Glasgow coma scale score 3-8, 24 hours or more after hospital admission

• R40.2440 - Other coma, without documented Glasgow coma scale score, or with partial score reported, unspecified time

• R40.2441 - Other coma, without documented Glasgow coma scale score, or with partial score reported, in the field [EMT or ambulance]

• R40.2442 - Other coma, without documented Glasgow coma scale score, or with partial score reported, at arrival to emergency department

• R40.2443 - Other coma, without documented Glasgow coma scale score, or with partial score reported, at hospital admission

• R40.2444 - Other coma, without documented Glasgow coma scale score, or with partial score reported, 24 hours or more after hospital admission

• R40.2A - Nontraumatic coma due to underlying condition

Other symptoms and signs involving cognitive functions and awareness (R41)

• R41.83 - Borderline intellectual functioning

Symptoms and signs involving emotional state (R45)

• R45.850 - Homicidal ideations

Symptoms and signs involving appearance and behavior (R46)

• R46.81 - Obsessive-compulsive behavior

• R46.89 - Other symptoms and signs involving appearance and behavior

Symptoms and signs specifically associated with systemic inflammation and infection (R65)

• R65.10 - Systemic inflammatory response syndrome (SIRS) of non-infectious origin without acute organ dysfunction

• R65.11 - Systemic inflammatory response syndrome (SIRS) of non-infectious origin with acute organ dysfunction

• R65.20 - Severe sepsis without septic shock

• R65.21 - Severe sepsis with septic shock

Intracranial injury (S06)

• S06.A0XA - Traumatic brain compression without herniation, initial encounter

• S06.A0XD - Traumatic brain compression without herniation, subsequent encounter

• S06.A0XS - Traumatic brain compression without herniation, sequela

• S06.A1XA - Traumatic brain compression with herniation, initial encounter

• S06.A1XD - Traumatic brain compression with herniation, subsequent encounter

• S06.A1XS - Traumatic brain compression with herniation, sequela

Poisoning by, adverse effect of and underdosing of systemic antibiotics (T36)

• T36.0X5A - Adverse effect of penicillins, initial encounter

• T36.0X5D - Adverse effect of penicillins, subsequent encounter

• T36.0X5S - Adverse effect of penicillins, sequela

• T36.0X6A - Underdosing of penicillins, initial encounter

• T36.0X6D - Underdosing of penicillins, subsequent encounter

• T36.0X6S - Underdosing of penicillins, sequela

• T36.1X5A - Adverse effect of cephalosporins and other beta-lactam antibiotics, initial encounter

• T36.1X5D - Adverse effect of cephalosporins and other beta-lactam antibiotics, subsequent encounter

• T36.1X5S - Adverse effect of cephalosporins and other beta-lactam antibiotics, sequela

• T36.1X6A - Underdosing of cephalosporins and other beta-lactam antibiotics, initial encounter

• T36.1X6D - Underdosing of cephalosporins and other beta-lactam antibiotics, subsequent encounter

• T36.1X6S - Underdosing of cephalosporins and other beta-lactam antibiotics, sequela

• T36.2X5A - Adverse effect of chloramphenicol group, initial encounter

• T36.2X5D - Adverse effect of chloramphenicol group, subsequent encounter

• T36.2X5S - Adverse effect of chloramphenicol group, sequela

• T36.2X6A - Underdosing of chloramphenicol group, initial encounter

• T36.2X6D - Underdosing of chloramphenicol group, subsequent encounter

• T36.2X6S - Underdosing of chloramphenicol group, sequela

• T36.3X5A - Adverse effect of macrolides, initial encounter

• T36.3X5D - Adverse effect of macrolides, subsequent encounter

• T36.3X5S - Adverse effect of macrolides, sequela

• T36.3X6A - Underdosing of macrolides, initial encounter

• T36.3X6D - Underdosing of macrolides, subsequent encounter

• T36.3X6S - Underdosing of macrolides, sequela

• T36.4X5A - Adverse effect of tetracyclines, initial encounter

• T36.4X5D - Adverse effect of tetracyclines, subsequent encounter

• T36.4X5S - Adverse effect of tetracyclines, sequela

• T36.4X6A - Underdosing of tetracyclines, initial encounter

• T36.4X6D - Underdosing of tetracyclines, subsequent encounter

• T36.4X6S - Underdosing of tetracyclines, sequela

• T36.5X5A - Adverse effect of aminoglycosides, initial encounter

• T36.5X5D - Adverse effect of aminoglycosides, subsequent encounter

• T36.5X5S - Adverse effect of aminoglycosides, sequela

• T36.5X6A - Underdosing of aminoglycosides, initial encounter

• T36.5X6D - Underdosing of aminoglycosides, subsequent encounter

• T36.5X6S - Underdosing of aminoglycosides, sequela

• T36.6X5A - Adverse effect of rifampicins, initial encounter

• T36.6X5D - Adverse effect of rifampicins, subsequent encounter

• T36.6X5S - Adverse effect of rifampicins, sequela

• T36.6X6A - Underdosing of rifampicins, initial encounter

• T36.6X6D - Underdosing of rifampicins, subsequent encounter

• T36.6X6S - Underdosing of rifampicins, sequela

• T36.7X5A - Adverse effect of antifungal antibiotics, systemically used, initial encounter

• T36.7X5D - Adverse effect of antifungal antibiotics, systemically used, subsequent encounter

• T36.7X5S - Adverse effect of antifungal antibiotics, systemically used, sequela

• T36.7X6A - Underdosing of antifungal antibiotics, systemically used, initial encounter

• T36.7X6D - Underdosing of antifungal antibiotics, systemically used, subsequent encounter

• T36.7X6S - Underdosing of antifungal antibiotics, systemically used, sequela

• T36.8X5A - Adverse effect of other systemic antibiotics, initial encounter

• T36.8X5D - Adverse effect of other systemic antibiotics, subsequent encounter

• T36.8X5S - Adverse effect of other systemic antibiotics, sequela

• T36.8X6A - Underdosing of other systemic antibiotics, initial encounter

• T36.8X6D - Underdosing of other systemic antibiotics, subsequent encounter

• T36.8X6S - Underdosing of other systemic antibiotics, sequela

• T36.95XA - Adverse effect of unspecified systemic antibiotic, initial encounter

• T36.95XD - Adverse effect of unspecified systemic antibiotic, subsequent encounter

• T36.95XS - Adverse effect of unspecified systemic antibiotic, sequela

• T36.96XA - Underdosing of unspecified systemic antibiotic, initial encounter

• T36.96XD - Underdosing of unspecified systemic antibiotic, subsequent encounter

• T36.96XS - Underdosing of unspecified systemic antibiotic, sequela

Poisoning by, adverse effect of and underdosing of other systemic anti-infectives and antiparasitics (T37)

• T37.0X5A - Adverse effect of sulfonamides, initial encounter

• T37.0X5D - Adverse effect of sulfonamides, subsequent encounter

• T37.0X5S - Adverse effect of sulfonamides, sequela

• T37.0X6A - Underdosing of sulfonamides, initial encounter

• T37.0X6D - Underdosing of sulfonamides, subsequent encounter

• T37.0X6S - Underdosing of sulfonamides, sequela

• T37.1X5A - Adverse effect of antimycobacterial drugs, initial encounter

• T37.1X5D - Adverse effect of antimycobacterial drugs, subsequent encounter

• T37.1X5S - Adverse effect of antimycobacterial drugs, sequela

• T37.1X6A - Underdosing of antimycobacterial drugs, initial encounter

• T37.1X6D - Underdosing of antimycobacterial drugs, subsequent encounter

• T37.1X6S - Underdosing of antimycobacterial drugs, sequela

• T37.2X5A - Adverse effect of antimalarials and drugs acting on other blood protozoa, initial encounter

• T37.2X5D - Adverse effect of antimalarials and drugs acting on other blood protozoa, subsequent encounter

• T37.2X5S - Adverse effect of antimalarials and drugs acting on other blood protozoa, sequela

• T37.2X6A - Underdosing of antimalarials and drugs acting on other blood protozoa, initial encounter

• T37.2X6D - Underdosing of antimalarials and drugs acting on other blood protozoa, subsequent encounter

• T37.2X6S - Underdosing of antimalarials and drugs acting on other blood protozoa, sequela

• T37.3X5A - Adverse effect of other antiprotozoal drugs, initial encounter

• T37.3X5D - Adverse effect of other antiprotozoal drugs, subsequent encounter

• T37.3X5S - Adverse effect of other antiprotozoal drugs, sequela

• T37.3X6A - Underdosing of other antiprotozoal drugs, initial encounter

• T37.3X6D - Underdosing of other antiprotozoal drugs, subsequent encounter

• T37.3X6S - Underdosing of other antiprotozoal drugs, sequela

• T37.4X5A - Adverse effect of anthelminthics, initial encounter

• T37.4X5D - Adverse effect of anthelminthics, subsequent encounter

• T37.4X5S - Adverse effect of anthelminthics, sequela

• T37.4X6A - Underdosing of anthelminthics, initial encounter

• T37.4X6D - Underdosing of anthelminthics, subsequent encounter

• T37.4X6S - Underdosing of anthelminthics, sequela

• T37.5X5A - Adverse effect of antiviral drugs, initial encounter

• T37.5X5D - Adverse effect of antiviral drugs, subsequent encounter

• T37.5X5S - Adverse effect of antiviral drugs, sequela

• T37.5X6A - Underdosing of antiviral drugs, initial encounter

• T37.5X6D - Underdosing of antiviral drugs, subsequent encounter

• T37.5X6S - Underdosing of antiviral drugs, sequela

• T37.8X5A - Adverse effect of other specified systemic anti-infectives and antiparasitics, initial encounter

• T37.8X5D - Adverse effect of other specified systemic anti-infectives and antiparasitics, subsequent encounter

• T37.8X5S - Adverse effect of other specified systemic anti-infectives and antiparasitics, sequela

• T37.8X6A - Underdosing of other specified systemic anti-infectives and antiparasitics, initial encounter

• T37.8X6D - Underdosing of other specified systemic anti-infectives and antiparasitics, subsequent encounter

• T37.8X6S - Underdosing of other specified systemic anti-infectives and antiparasitics, sequela

• T37.95XA - Adverse effect of unspecified systemic anti-infective and antiparasitic, initial encounter

• T37.95XD - Adverse effect of unspecified systemic anti-infective and antiparasitic, subsequent encounter

• T37.95XS - Adverse effect of unspecified systemic anti-infective and antiparasitic, sequela

• T37.96XA - Underdosing of unspecified systemic anti-infectives and antiparasitics, initial encounter

• T37.96XD - Underdosing of unspecified systemic anti-infectives and antiparasitics, subsequent encounter

• T37.96XS - Underdosing of unspecified systemic anti-infectives and antiparasitics, sequela

Poisoning by, adverse effect of and underdosing of hormones and their synthetic substitutes and antagonists, not elsewhere classified (T38)

• T38.0X5A - Adverse effect of glucocorticoids and synthetic analogues, initial encounter

• T38.0X5D - Adverse effect of glucocorticoids and synthetic analogues, subsequent encounter

• T38.0X5S - Adverse effect of glucocorticoids and synthetic analogues, sequela

• T38.0X6A - Underdosing of glucocorticoids and synthetic analogues, initial encounter

• T38.0X6D - Underdosing of glucocorticoids and synthetic analogues, subsequent encounter

• T38.0X6S - Underdosing of glucocorticoids and synthetic analogues, sequela

• T38.1X5A - Adverse effect of thyroid hormones and substitutes, initial encounter

• T38.1X5D - Adverse effect of thyroid hormones and substitutes, subsequent encounter

• T38.1X5S - Adverse effect of thyroid hormones and substitutes, sequela

• T38.1X6A - Underdosing of thyroid hormones and substitutes, initial encounter

• T38.1X6D - Underdosing of thyroid hormones and substitutes, subsequent encounter

• T38.1X6S - Underdosing of thyroid hormones and substitutes, sequela

• T38.2X5A - Adverse effect of antithyroid drugs, initial encounter

• T38.2X5D - Adverse effect of antithyroid drugs, subsequent encounter

• T38.2X5S - Adverse effect of antithyroid drugs, sequela

• T38.2X6A - Underdosing of antithyroid drugs, initial encounter

• T38.2X6D - Underdosing of antithyroid drugs, subsequent encounter

• T38.2X6S - Underdosing of antithyroid drugs, sequela

• T38.3X5A - Adverse effect of insulin and oral hypoglycemic [antidiabetic] drugs, initial encounter

• T38.3X5D - Adverse effect of insulin and oral hypoglycemic [antidiabetic] drugs, subsequent encounter

• T38.3X5S - Adverse effect of insulin and oral hypoglycemic [antidiabetic] drugs, sequela

• T38.3X6A - Underdosing of insulin and oral hypoglycemic [antidiabetic] drugs, initial encounter

• T38.3X6D - Underdosing of insulin and oral hypoglycemic [antidiabetic] drugs, subsequent encounter

• T38.3X6S - Underdosing of insulin and oral hypoglycemic [antidiabetic] drugs, sequela

• T38.4X5A - Adverse effect of oral contraceptives, initial encounter

• T38.4X5D - Adverse effect of oral contraceptives, subsequent encounter

• T38.4X5S - Adverse effect of oral contraceptives, sequela

• T38.4X6A - Underdosing of oral contraceptives, initial encounter

• T38.4X6D - Underdosing of oral contraceptives, subsequent encounter

• T38.4X6S - Underdosing of oral contraceptives, sequela

• T38.5X5A - Adverse effect of other estrogens and progestogens, initial encounter

• T38.5X5D - Adverse effect of other estrogens and progestogens, subsequent encounter

• T38.5X5S - Adverse effect of other estrogens and progestogens, sequela

• T38.5X6A - Underdosing of other estrogens and progestogens, initial encounter

• T38.5X6D - Underdosing of other estrogens and progestogens, subsequent encounter

• T38.5X6S - Underdosing of other estrogens and progestogens, sequela

• T38.6X5A - Adverse effect of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, initial encounter

• T38.6X5D - Adverse effect of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, subsequent encounter

• T38.6X5S - Adverse effect of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, sequela

• T38.6X6A - Underdosing of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, initial encounter

• T38.6X6D - Underdosing of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, subsequent encounter

• T38.6X6S - Underdosing of antigonadotrophins, antiestrogens, antiandrogens, not elsewhere classified, sequela

• T38.7X5A - Adverse effect of androgens and anabolic congeners, initial encounter

• T38.7X5D - Adverse effect of androgens and anabolic congeners, subsequent encounter

• T38.7X5S - Adverse effect of androgens and anabolic congeners, sequela

• T38.7X6A - Underdosing of androgens and anabolic congeners, initial encounter

• T38.7X6D - Underdosing of androgens and anabolic congeners, subsequent encounter

• T38.7X6S - Underdosing of androgens and anabolic congeners, sequela

• T38.805A - Adverse effect of unspecified hormones and synthetic substitutes, initial encounter

• T38.805D - Adverse effect of unspecified hormones and synthetic substitutes, subsequent encounter

• T38.805S - Adverse effect of unspecified hormones and synthetic substitutes, sequela

• T38.806A - Underdosing of unspecified hormones and synthetic substitutes, initial encounter

• T38.806D - Underdosing of unspecified hormones and synthetic substitutes, subsequent encounter

• T38.806S - Underdosing of unspecified hormones and synthetic substitutes, sequela

• T38.815A - Adverse effect of anterior pituitary [adenohypophyseal] hormones, initial encounter

• T38.815D - Adverse effect of anterior pituitary [adenohypophyseal] hormones, subsequent encounter

• T38.815S - Adverse effect of anterior pituitary [adenohypophyseal] hormones, sequela

• T38.816A - Underdosing of anterior pituitary [adenohypophyseal] hormones, initial encounter

• T38.816D - Underdosing of anterior pituitary [adenohypophyseal] hormones, subsequent encounter

• T38.816S - Underdosing of anterior pituitary [adenohypophyseal] hormones, sequela

• T38.895A - Adverse effect of other hormones and synthetic substitutes, initial encounter

• T38.895D - Adverse effect of other hormones and synthetic substitutes, subsequent encounter

• T38.895S - Adverse effect of other hormones and synthetic substitutes, sequela

• T38.896A - Underdosing of other hormones and synthetic substitutes, initial encounter

• T38.896D - Underdosing of other hormones and synthetic substitutes, subsequent encounter

• T38.896S - Underdosing of other hormones and synthetic substitutes, sequela

• T38.905A - Adverse effect of unspecified hormone antagonists, initial encounter

• T38.905D - Adverse effect of unspecified hormone antagonists, subsequent encounter

• T38.905S - Adverse effect of unspecified hormone antagonists, sequela

• T38.906A - Underdosing of unspecified hormone antagonists, initial encounter

• T38.906D - Underdosing of unspecified hormone antagonists, subsequent encounter

• T38.906S - Underdosing of unspecified hormone antagonists, sequela

• T38.995A - Adverse effect of other hormone antagonists, initial encounter

• T38.995D - Adverse effect of other hormone antagonists, subsequent encounter

• T38.995S - Adverse effect of other hormone antagonists, sequela

• T38.996A - Underdosing of other hormone antagonists, initial encounter

• T38.996D - Underdosing of other hormone antagonists, subsequent encounter

• T38.996S - Underdosing of other hormone antagonists, sequela

Poisoning by, adverse effect of and underdosing of nonopioid analgesics, antipyretics and antirheumatics (T39)

• T39.015A - Adverse effect of aspirin, initial encounter

• T39.015D - Adverse effect of aspirin, subsequent encounter

• T39.015S - Adverse effect of aspirin, sequela

• T39.016A - Underdosing of aspirin, initial encounter

• T39.016D - Underdosing of aspirin, subsequent encounter

• T39.016S - Underdosing of aspirin, sequela

• T39.095A - Adverse effect of salicylates, initial encounter

• T39.095D - Adverse effect of salicylates, subsequent encounter

• T39.095S - Adverse effect of salicylates, sequela

• T39.096A - Underdosing of salicylates, initial encounter

• T39.096D - Underdosing of salicylates, subsequent encounter

• T39.096S - Underdosing of salicylates, sequela

• T39.1X5A - Adverse effect of 4-Aminophenol derivatives, initial encounter

• T39.1X5D - Adverse effect of 4-Aminophenol derivatives, subsequent encounter

• T39.1X5S - Adverse effect of 4-Aminophenol derivatives, sequela

• T39.1X6A - Underdosing of 4-Aminophenol derivatives, initial encounter

• T39.1X6D - Underdosing of 4-Aminophenol derivatives, subsequent encounter

• T39.1X6S - Underdosing of 4-Aminophenol derivatives, sequela

• T39.2X5A - Adverse effect of pyrazolone derivatives, initial encounter

• T39.2X5D - Adverse effect of pyrazolone derivatives, subsequent encounter

• T39.2X5S - Adverse effect of pyrazolone derivatives, sequela

• T39.2X6A - Underdosing of pyrazolone derivatives, initial encounter

• T39.2X6D - Underdosing of pyrazolone derivatives, subsequent encounter

• T39.2X6S - Underdosing of pyrazolone derivatives, sequela

• T39.315A - Adverse effect of propionic acid derivatives, initial encounter

• T39.315D - Adverse effect of propionic acid derivatives, subsequent encounter

• T39.315S - Adverse effect of propionic acid derivatives, sequela

• T39.316A - Underdosing of propionic acid derivatives, initial encounter

• T39.316D - Underdosing of propionic acid derivatives, subsequent encounter

• T39.316S - Underdosing of propionic acid derivatives, sequela

• T39.395A - Adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], initial encounter

• T39.395D - Adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], subsequent encounter

• T39.395S - Adverse effect of other nonsteroidal anti-inflammatory drugs [NSAID], sequela

• T39.396A - Underdosing of other nonsteroidal anti-inflammatory drugs [NSAID], initial encounter

• T39.396D - Underdosing of other nonsteroidal anti-inflammatory drugs [NSAID], subsequent encounter

• T39.396S - Underdosing of other nonsteroidal anti-inflammatory drugs [NSAID], sequela

• T39.4X5A - Adverse effect of antirheumatics, not elsewhere classified, initial encounter

• T39.4X5D - Adverse effect of antirheumatics, not elsewhere classified, subsequent encounter

• T39.4X5S - Adverse effect of antirheumatics, not elsewhere classified, sequela

• T39.4X6A - Underdosing of antirheumatics, not elsewhere classified, initial encounter

• T39.4X6D - Underdosing of antirheumatics, not elsewhere classified, subsequent encounter

• T39.4X6S - Underdosing of antirheumatics, not elsewhere classified, sequela

• T39.8X5A - Adverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified, initial encounter

• T39.8X5D - Adverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified, subsequent encounter

• T39.8X5S - Adverse effect of other nonopioid analgesics and antipyretics, not elsewhere classified, sequela

• T39.8X6A - Underdosing of other nonopioid analgesics and antipyretics, not elsewhere classified, initial encounter

• T39.8X6D - Underdosing of other nonopioid analgesics and antipyretics, not elsewhere classified, subsequent encounter

• T39.8X6S - Underdosing of other nonopioid analgesics and antipyretics, not elsewhere classified, sequela

• T39.95XA - Adverse effect of unspecified nonopioid analgesic, antipyretic and antirheumatic, initial encounter

• T39.95XD - Adverse effect of unspecified nonopioid analgesic, antipyretic and antirheumatic, subsequent encounter

• T39.95XS - Adverse effect of unspecified nonopioid analgesic, antipyretic and antirheumatic, sequela

• T39.96XA - Underdosing of unspecified nonopioid analgesic, antipyretic and antirheumatic, initial encounter

• T39.96XD - Underdosing of unspecified nonopioid analgesic, antipyretic and antirheumatic, subsequent encounter

• T39.96XS - Underdosing of unspecified nonopioid analgesic, antipyretic and antirheumatic, sequela

Poisoning by, adverse effect of and underdosing of narcotics and psychodysleptics [hallucinogens] (T40)

• T40.0X5A - Adverse effect of opium, initial encounter

• T40.0X5D - Adverse effect of opium, subsequent encounter

• T40.0X5S - Adverse effect of opium, sequela

• T40.0X6A - Underdosing of opium, initial encounter

• T40.0X6D - Underdosing of opium, subsequent encounter

• T40.0X6S - Underdosing of opium, sequela

• T40.2X5A - Adverse effect of other opioids, initial encounter

• T40.2X5D - Adverse effect of other opioids, subsequent encounter

• T40.2X5S - Adverse effect of other opioids, sequela

• T40.2X6A - Underdosing of other opioids, initial encounter

• T40.2X6D - Underdosing of other opioids, subsequent encounter

• T40.2X6S - Underdosing of other opioids, sequela

• T40.3X5A - Adverse effect of methadone, initial encounter

• T40.3X5D - Adverse effect of methadone, subsequent encounter

• T40.3X5S - Adverse effect of methadone, sequela

• T40.3X6A - Underdosing of methadone, initial encounter

• T40.3X6D - Underdosing of methadone, subsequent encounter

• T40.3X6S - Underdosing of methadone, sequela

• T40.415A - Adverse effect of fentanyl or fentanyl analogs, initial encounter

• T40.415D - Adverse effect of fentanyl or fentanyl analogs, subsequent encounter

• T40.415S - Adverse effect of fentanyl or fentanyl analogs, sequela

• T40.416A - Underdosing of fentanyl or fentanyl analogs, initial encounter

• T40.416D - Underdosing of fentanyl or fentanyl analogs, subsequent encounter

• T40.416S - Underdosing of fentanyl or fentanyl analogs, sequela

• T40.425A - Adverse effect of tramadol, initial encounter

• T40.425D - Adverse effect of tramadol, subsequent encounter

• T40.425S - Adverse effect of tramadol, sequela

• T40.426A - Underdosing of tramadol, initial encounter

• T40.426D - Underdosing of tramadol, subsequent encounter

• T40.426S - Underdosing of tramadol, sequela

• T40.495A - Adverse effect of other synthetic narcotics, initial encounter

• T40.495D - Adverse effect of other synthetic narcotics, subsequent encounter

• T40.495S - Adverse effect of other synthetic narcotics, sequela

• T40.496A - Underdosing of other synthetic narcotics, initial encounter

• T40.496D - Underdosing of other synthetic narcotics, subsequent encounter

• T40.496S - Underdosing of other synthetic narcotics, sequela

• T40.5X5A - Adverse effect of cocaine, initial encounter

• T40.5X5D - Adverse effect of cocaine, subsequent encounter

• T40.5X5S - Adverse effect of cocaine, sequela

• T40.5X6A - Underdosing of cocaine, initial encounter

• T40.5X6D - Underdosing of cocaine, subsequent encounter

• T40.5X6S - Underdosing of cocaine, sequela

• T40.605A - Adverse effect of unspecified narcotics, initial encounter

• T40.605D - Adverse effect of unspecified narcotics, subsequent encounter

• T40.605S - Adverse effect of unspecified narcotics, sequela

• T40.606A - Underdosing of unspecified narcotics, initial encounter

• T40.606D - Underdosing of unspecified narcotics, subsequent encounter

• T40.606S - Underdosing of unspecified narcotics, sequela

• T40.695A - Adverse effect of other narcotics, initial encounter

• T40.695D - Adverse effect of other narcotics, subsequent encounter

• T40.695S - Adverse effect of other narcotics, sequela

• T40.696A - Underdosing of other narcotics, initial encounter

• T40.696D - Underdosing of other narcotics, subsequent encounter

• T40.696S - Underdosing of other narcotics, sequela

• T40.715A - Adverse effect of cannabis, initial encounter

• T40.715D - Adverse effect of cannabis, subsequent encounter

• T40.715S - Adverse effect of cannabis, sequela

• T40.716A - Underdosing of cannabis, initial encounter

• T40.716D - Underdosing of cannabis, subsequent encounter

• T40.716S - Underdosing of cannabis, sequela

• T40.725A - Adverse effect of synthetic cannabinoids, initial encounter

• T40.725D - Adverse effect of synthetic cannabinoids, subsequent encounter

• T40.725S - Adverse effect of synthetic cannabinoids, sequela

• T40.726A - Underdosing of synthetic cannabinoids, initial encounter

• T40.726D - Underdosing of synthetic cannabinoids, subsequent encounter

• T40.726S - Underdosing of synthetic cannabinoids, sequela

• T40.905A - Adverse effect of unspecified psychodysleptics [hallucinogens], initial encounter

• T40.905D - Adverse effect of unspecified psychodysleptics [hallucinogens], subsequent encounter

• T40.905S - Adverse effect of unspecified psychodysleptics [hallucinogens], sequela

• T40.906A - Underdosing of unspecified psychodysleptics [hallucinogens], initial encounter

• T40.906D - Underdosing of unspecified psychodysleptics [hallucinogens], subsequent encounter

• T40.906S - Underdosing of unspecified psychodysleptics [hallucinogens], sequela

• T40.995A - Adverse effect of other psychodysleptics [hallucinogens], initial encounter

• T40.995D - Adverse effect of other psychodysleptics [hallucinogens], subsequent encounter

• T40.995S - Adverse effect of other psychodysleptics [hallucinogens], sequela

• T40.996A - Underdosing of other psychodysleptics [hallucinogens], initial encounter

• T40.996D - Underdosing of other psychodysleptics [hallucinogens], subsequent encounter

• T40.996S - Underdosing of other psychodysleptics [hallucinogens], sequela

Poisoning by, adverse effect of and underdosing of anesthetics and therapeutic gases (T41)

• T41.0X5A - Adverse effect of inhaled anesthetics, initial encounter

• T41.0X5D - Adverse effect of inhaled anesthetics, subsequent encounter

• T41.0X5S - Adverse effect of inhaled anesthetics, sequela

• T41.0X6A - Underdosing of inhaled anesthetics, initial encounter

• T41.0X6D - Underdosing of inhaled anesthetics, subsequent encounter

• T41.0X6S - Underdosing of inhaled anesthetics, sequela

• T41.1X5A - Adverse effect of intravenous anesthetics, initial encounter

• T41.1X5D - Adverse effect of intravenous anesthetics, subsequent encounter

• T41.1X5S - Adverse effect of intravenous anesthetics, sequela

• T41.1X6A - Underdosing of intravenous anesthetics, initial encounter

• T41.1X6D - Underdosing of intravenous anesthetics, subsequent encounter

• T41.1X6S - Underdosing of intravenous anesthetics, sequela

• T41.205A - Adverse effect of unspecified general anesthetics, initial encounter

• T41.205D - Adverse effect of unspecified general anesthetics, subsequent encounter

• T41.205S - Adverse effect of unspecified general anesthetics, sequela

• T41.206A - Underdosing of unspecified general anesthetics, initial encounter

• T41.206D - Underdosing of unspecified general anesthetics, subsequent encounter

• T41.206S - Underdosing of unspecified general anesthetics, sequela

• T41.295A - Adverse effect of other general anesthetics, initial encounter

• T41.295D - Adverse effect of other general anesthetics, subsequent encounter

• T41.295S - Adverse effect of other general anesthetics, sequela

• T41.296A - Underdosing of other general anesthetics, initial encounter

• T41.296D - Underdosing of other general anesthetics, subsequent encounter

• T41.296S - Underdosing of other general anesthetics, sequela

• T41.3X5A - Adverse effect of local anesthetics, initial encounter

• T41.3X5D - Adverse effect of local anesthetics, subsequent encounter

• T41.3X5S - Adverse effect of local anesthetics, sequela

• T41.3X6A - Underdosing of local anesthetics, initial encounter

• T41.3X6D - Underdosing of local anesthetics, subsequent encounter

• T41.3X6S - Underdosing of local anesthetics, sequela

• T41.45XA - Adverse effect of unspecified anesthetic, initial encounter

• T41.45XD - Adverse effect of unspecified anesthetic, subsequent encounter

• T41.45XS - Adverse effect of unspecified anesthetic, sequela

• T41.46XA - Underdosing of unspecified anesthetics, initial encounter

• T41.46XD - Underdosing of unspecified anesthetics, subsequent encounter

• T41.46XS - Underdosing of unspecified anesthetics, sequela

• T41.5X5A - Adverse effect of therapeutic gases, initial encounter

• T41.5X5D - Adverse effect of therapeutic gases, subsequent encounter

• T41.5X5S - Adverse effect of therapeutic gases, sequela

• T41.5X6A - Underdosing of therapeutic gases, initial encounter

• T41.5X6D - Underdosing of therapeutic gases, subsequent encounter

• T41.5X6S - Underdosing of therapeutic gases, sequela

Poisoning by, adverse effect of and underdosing of antiepileptic, sedative- hypnotic and antiparkinsonism drugs (T42)

• T42.0X5A - Adverse effect of hydantoin derivatives, initial encounter

• T42.0X5D - Adverse effect of hydantoin derivatives, subsequent encounter

• T42.0X5S - Adverse effect of hydantoin derivatives, sequela

• T42.0X6A - Underdosing of hydantoin derivatives, initial encounter

• T42.0X6D - Underdosing of hydantoin derivatives, subsequent encounter

• T42.0X6S - Underdosing of hydantoin derivatives, sequela

• T42.1X5A - Adverse effect of iminostilbenes, initial encounter

• T42.1X5D - Adverse effect of iminostilbenes, subsequent encounter

• T42.1X5S - Adverse effect of iminostilbenes, sequela

• T42.1X6A - Underdosing of iminostilbenes, initial encounter

• T42.1X6D - Underdosing of iminostilbenes, subsequent encounter

• T42.1X6S - Underdosing of iminostilbenes, sequela

• T42.2X5A - Adverse effect of succinimides and oxazolidinediones, initial encounter

• T42.2X5D - Adverse effect of succinimides and oxazolidinediones, subsequent encounter

• T42.2X5S - Adverse effect of succinimides and oxazolidinediones, sequela

• T42.2X6A - Underdosing of succinimides and oxazolidinediones, initial encounter

• T42.2X6D - Underdosing of succinimides and oxazolidinediones, subsequent encounter

• T42.2X6S - Underdosing of succinimides and oxazolidinediones, sequela

• T42.3X5A - Adverse effect of barbiturates, initial encounter

• T42.3X5D - Adverse effect of barbiturates, subsequent encounter

• T42.3X5S - Adverse effect of barbiturates, sequela

• T42.3X6A - Underdosing of barbiturates, initial encounter

• T42.3X6D - Underdosing of barbiturates, subsequent encounter

• T42.3X6S - Underdosing of barbiturates, sequela

• T42.4X5A - Adverse effect of benzodiazepines, initial encounter

• T42.4X5D - Adverse effect of benzodiazepines, subsequent encounter

• T42.4X5S - Adverse effect of benzodiazepines, sequela

• T42.4X6A - Underdosing of benzodiazepines, initial encounter

• T42.4X6D - Underdosing of benzodiazepines, subsequent encounter

• T42.4X6S - Underdosing of benzodiazepines, sequela

• T42.5X5A - Adverse effect of mixed antiepileptics, initial encounter

• T42.5X5D - Adverse effect of mixed antiepileptics, subsequent encounter

• T42.5X5S - Adverse effect of mixed antiepileptics, sequela

• T42.5X6A - Underdosing of mixed antiepileptics, initial encounter

• T42.5X6D - Underdosing of mixed antiepileptics, subsequent encounter

• T42.5X6S - Underdosing of mixed antiepileptics, sequela

• T42.6X5A - Adverse effect of other antiepileptic and sedative-hypnotic drugs, initial encounter

• T42.6X5D - Adverse effect of other antiepileptic and sedative-hypnotic drugs, subsequent encounter

• T42.6X5S - Adverse effect of other antiepileptic and sedative-hypnotic drugs, sequela

• T42.6X6A - Underdosing of other antiepileptic and sedative-hypnotic drugs, initial encounter

• T42.6X6D - Underdosing of other antiepileptic and sedative-hypnotic drugs, subsequent encounter

• T42.6X6S - Underdosing of other antiepileptic and sedative-hypnotic drugs, sequela

• T42.75XA - Adverse effect of unspecified antiepileptic and sedative-hypnotic drugs, initial encounter

• T42.75XD - Adverse effect of unspecified antiepileptic and sedative-hypnotic drugs, subsequent encounter

• T42.75XS - Adverse effect of unspecified antiepileptic and sedative-hypnotic drugs, sequela

• T42.76XA - Underdosing of unspecified antiepileptic and sedative-hypnotic drugs, initial encounter

• T42.76XD - Underdosing of unspecified antiepileptic and sedative-hypnotic drugs, subsequent encounter

• T42.76XS - Underdosing of unspecified antiepileptic and sedative-hypnotic drugs, sequela

• T42.8X5A - Adverse effect of antiparkinsonism drugs and other central muscle-tone depressants, initial encounter

• T42.8X5D - Adverse effect of antiparkinsonism drugs and other central muscle-tone depressants, subsequent encounter

• T42.8X5S - Adverse effect of antiparkinsonism drugs and other central muscle-tone depressants, sequela

• T42.8X6A - Underdosing of antiparkinsonism drugs and other central muscle-tone depressants, initial encounter

• T42.8X6D - Underdosing of antiparkinsonism drugs and other central muscle-tone depressants, subsequent encounter

• T42.8X6S - Underdosing of antiparkinsonism drugs and other central muscle-tone depressants, sequela

Poisoning by, adverse effect of and underdosing of psychotropic drugs, not elsewhere classified (T43)

• T43.015A - Adverse effect of tricyclic antidepressants, initial encounter

• T43.015D - Adverse effect of tricyclic antidepressants, subsequent encounter

• T43.015S - Adverse effect of tricyclic antidepressants, sequela

• T43.016A - Underdosing of tricyclic antidepressants, initial encounter

• T43.016D - Underdosing of tricyclic antidepressants, subsequent encounter

• T43.016S - Underdosing of tricyclic antidepressants, sequela

• T43.025A - Adverse effect of tetracyclic antidepressants, initial encounter

• T43.025D - Adverse effect of tetracyclic antidepressants, subsequent encounter

• T43.025S - Adverse effect of tetracyclic antidepressants, sequela

• T43.026A - Underdosing of tetracyclic antidepressants, initial encounter

• T43.026D - Underdosing of tetracyclic antidepressants, subsequent encounter

• T43.026S - Underdosing of tetracyclic antidepressants, sequela

• T43.1X5A - Adverse effect of monoamine-oxidase-inhibitor antidepressants, initial encounter

• T43.1X5D - Adverse effect of monoamine-oxidase-inhibitor antidepressants, subsequent encounter

• T43.1X5S - Adverse effect of monoamine-oxidase-inhibitor antidepressants, sequela

• T43.1X6A - Underdosing of monoamine-oxidase-inhibitor antidepressants, initial encounter

• T43.1X6D - Underdosing of monoamine-oxidase-inhibitor antidepressants, subsequent encounter

• T43.1X6S - Underdosing of monoamine-oxidase-inhibitor antidepressants, sequela

• T43.205A - Adverse effect of unspecified antidepressants, initial encounter

• T43.205D - Adverse effect of unspecified antidepressants, subsequent encounter

• T43.205S - Adverse effect of unspecified antidepressants, sequela

• T43.206A - Underdosing of unspecified antidepressants, initial encounter

• T43.206D - Underdosing of unspecified antidepressants, subsequent encounter

• T43.206S - Underdosing of unspecified antidepressants, sequela

• T43.215A - Adverse effect of selective serotonin and norepinephrine reuptake inhibitors, initial encounter

• T43.215D - Adverse effect of selective serotonin and norepinephrine reuptake inhibitors, subsequent encounter

• T43.215S - Adverse effect of selective serotonin and norepinephrine reuptake inhibitors, sequela

• T43.216A - Underdosing of selective serotonin and norepinephrine reuptake inhibitors, initial encounter

• T43.216D - Underdosing of selective serotonin and norepinephrine reuptake inhibitors, subsequent encounter

• T43.216S - Underdosing of selective serotonin and norepinephrine reuptake inhibitors, sequela

• T43.225A - Adverse effect of selective serotonin reuptake inhibitors, initial encounter

• T43.225D - Adverse effect of selective serotonin reuptake inhibitors, subsequent encounter

• T43.225S - Adverse effect of selective serotonin reuptake inhibitors, sequela

• T43.226A - Underdosing of selective serotonin reuptake inhibitors, initial encounter

• T43.226D - Underdosing of selective serotonin reuptake inhibitors, subsequent encounter

• T43.226S - Underdosing of selective serotonin reuptake inhibitors, sequela

• T43.295A - Adverse effect of other antidepressants, initial encounter

• T43.295D - Adverse effect of other antidepressants, subsequent encounter

• T43.295S - Adverse effect of other antidepressants, sequela

• T43.296A - Underdosing of other antidepressants, initial encounter

• T43.296D - Underdosing of other antidepressants, subsequent encounter

• T43.296S - Underdosing of other antidepressants, sequela

• T43.3X5A - Adverse effect of phenothiazine antipsychotics and neuroleptics, initial encounter

• T43.3X5D - Adverse effect of phenothiazine antipsychotics and neuroleptics, subsequent encounter

• T43.3X5S - Adverse effect of phenothiazine antipsychotics and neuroleptics, sequela

• T43.3X6A - Underdosing of phenothiazine antipsychotics and neuroleptics, initial encounter

• T43.3X6D - Underdosing of phenothiazine antipsychotics and neuroleptics, subsequent encounter

• T43.3X6S - Underdosing of phenothiazine antipsychotics and neuroleptics, sequela

• T43.4X5A - Adverse effect of butyrophenone and thiothixene neuroleptics, initial encounter

• T43.4X5D - Adverse effect of butyrophenone and thiothixene neuroleptics, subsequent encounter

• T43.4X5S - Adverse effect of butyrophenone and thiothixene neuroleptics, sequela

• T43.4X6A - Underdosing of butyrophenone and thiothixene neuroleptics, initial encounter

• T43.4X6D - Underdosing of butyrophenone and thiothixene neuroleptics, subsequent encounter

• T43.4X6S - Underdosing of butyrophenone and thiothixene neuroleptics, sequela

• T43.505A - Adverse effect of unspecified antipsychotics and neuroleptics, initial encounter

• T43.505D - Adverse effect of unspecified antipsychotics and neuroleptics, subsequent encounter

• T43.505S - Adverse effect of unspecified antipsychotics and neuroleptics, sequela

• T43.506A - Underdosing of unspecified antipsychotics and neuroleptics, initial encounter

• T43.506D - Underdosing of unspecified antipsychotics and neuroleptics, subsequent encounter

• T43.506S - Underdosing of unspecified antipsychotics and neuroleptics, sequela

• T43.595A - Adverse effect of other antipsychotics and neuroleptics, initial encounter

• T43.595D - Adverse effect of other antipsychotics and neuroleptics, subsequent encounter

• T43.595S - Adverse effect of other antipsychotics and neuroleptics, sequela

• T43.596A - Underdosing of other antipsychotics and neuroleptics, initial encounter

• T43.596D - Underdosing of other antipsychotics and neuroleptics, subsequent encounter

• T43.596S - Underdosing of other antipsychotics and neuroleptics, sequela

• T43.605A - Adverse effect of unspecified psychostimulants, initial encounter

• T43.605D - Adverse effect of unspecified psychostimulants, subsequent encounter

• T43.605S - Adverse effect of unspecified psychostimulants, sequela

• T43.606A - Underdosing of unspecified psychostimulants, initial encounter

• T43.606D - Underdosing of unspecified psychostimulants, subsequent encounter

• T43.606S - Underdosing of unspecified psychostimulants, sequela

• T43.615A - Adverse effect of caffeine, initial encounter

• T43.615D - Adverse effect of caffeine, subsequent encounter

• T43.615S - Adverse effect of caffeine, sequela

• T43.616A - Underdosing of caffeine, initial encounter

• T43.616D - Underdosing of caffeine, subsequent encounter

• T43.616S - Underdosing of caffeine, sequela

• T43.625A - Adverse effect of amphetamines, initial encounter

• T43.625D - Adverse effect of amphetamines, subsequent encounter

• T43.625S - Adverse effect of amphetamines, sequela

• T43.626A - Underdosing of amphetamines, initial encounter

• T43.626D - Underdosing of amphetamines, subsequent encounter

• T43.626S - Underdosing of amphetamines, sequela

• T43.635A - Adverse effect of methylphenidate, initial encounter

• T43.635D - Adverse effect of methylphenidate, subsequent encounter

• T43.635S - Adverse effect of methylphenidate, sequela

• T43.636A - Underdosing of methylphenidate, initial encounter

• T43.636D - Underdosing of methylphenidate, subsequent encounter

• T43.636S - Underdosing of methylphenidate, sequela

• T43.655A - Adverse effect of methamphetamines, initial encounter

• T43.655D - Adverse effect of methamphetamines, subsequent encounter

• T43.655S - Adverse effect of methamphetamines, sequela

• T43.656A - Underdosing of methamphetamines, initial encounter

• T43.656D - Underdosing of methamphetamines, subsequent encounter

• T43.656S - Underdosing of methamphetamines, sequela

• T43.695A - Adverse effect of other psychostimulants, initial encounter

• T43.695D - Adverse effect of other psychostimulants, subsequent encounter

• T43.695S - Adverse effect of other psychostimulants, sequela

• T43.696A - Underdosing of other psychostimulants, initial encounter

• T43.696D - Underdosing of other psychostimulants, subsequent encounter

• T43.696S - Underdosing of other psychostimulants, sequela

• T43.8X5A - Adverse effect of other psychotropic drugs, initial encounter

• T43.8X5D - Adverse effect of other psychotropic drugs, subsequent encounter

• T43.8X5S - Adverse effect of other psychotropic drugs, sequela

• T43.8X6A - Underdosing of other psychotropic drugs, initial encounter

• T43.8X6D - Underdosing of other psychotropic drugs, subsequent encounter

• T43.8X6S - Underdosing of other psychotropic drugs, sequela

• T43.95XA - Adverse effect of unspecified psychotropic drug, initial encounter

• T43.95XD - Adverse effect of unspecified psychotropic drug, subsequent encounter

• T43.95XS - Adverse effect of unspecified psychotropic drug, sequela

• T43.96XA - Underdosing of unspecified psychotropic drug, initial encounter

• T43.96XD - Underdosing of unspecified psychotropic drug, subsequent encounter

• T43.96XS - Underdosing of unspecified psychotropic drug, sequela

Poisoning by, adverse effect of and underdosing of drugs primarily affecting the autonomic nervous system (T44)

• T44.0X5A - Adverse effect of anticholinesterase agents, initial encounter

• T44.0X5D - Adverse effect of anticholinesterase agents, subsequent encounter

• T44.0X5S - Adverse effect of anticholinesterase agents, sequela

• T44.0X6A - Underdosing of anticholinesterase agents, initial encounter

• T44.0X6D - Underdosing of anticholinesterase agents, subsequent encounter

• T44.0X6S - Underdosing of anticholinesterase agents, sequela

• T44.1X5A - Adverse effect of other parasympathomimetics [cholinergics], initial encounter

• T44.1X5D - Adverse effect of other parasympathomimetics [cholinergics], subsequent encounter

• T44.1X5S - Adverse effect of other parasympathomimetics [cholinergics], sequela

• T44.1X6A - Underdosing of other parasympathomimetics [cholinergics], initial encounter

• T44.1X6D - Underdosing of other parasympathomimetics [cholinergics], subsequent encounter

• T44.1X6S - Underdosing of other parasympathomimetics [cholinergics], sequela

• T44.2X5A - Adverse effect of ganglionic blocking drugs, initial encounter

• T44.2X5D - Adverse effect of ganglionic blocking drugs, subsequent encounter

• T44.2X5S - Adverse effect of ganglionic blocking drugs, sequela

• T44.2X6A - Underdosing of ganglionic blocking drugs, initial encounter

• T44.2X6D - Underdosing of ganglionic blocking drugs, subsequent encounter

• T44.2X6S - Underdosing of ganglionic blocking drugs, sequela

• T44.3X5A - Adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, initial encounter

• T44.3X5D - Adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, subsequent encounter

• T44.3X5S - Adverse effect of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, sequela

• T44.3X6A - Underdosing of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, initial encounter

• T44.3X6D - Underdosing of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, subsequent encounter

• T44.3X6S - Underdosing of other parasympatholytics [anticholinergics and antimuscarinics] and spasmolytics, sequela

• T44.4X5A - Adverse effect of predominantly alpha-adrenoreceptor agonists, initial encounter

• T44.4X5D - Adverse effect of predominantly alpha-adrenoreceptor agonists, subsequent encounter

• T44.4X5S - Adverse effect of predominantly alpha-adrenoreceptor agonists, sequela

• T44.4X6A - Underdosing of predominantly alpha-adrenoreceptor agonists, initial encounter

• T44.4X6D - Underdosing of predominantly alpha-adrenoreceptor agonists, subsequent encounter

• T44.4X6S - Underdosing of predominantly alpha-adrenoreceptor agonists, sequela

• T44.5X5A - Adverse effect of predominantly beta-adrenoreceptor agonists, initial encounter

• T44.5X5D - Adverse effect of predominantly beta-adrenoreceptor agonists, subsequent encounter

• T44.5X5S - Adverse effect of predominantly beta-adrenoreceptor agonists, sequela

• T44.5X6A - Underdosing of predominantly beta-adrenoreceptor agonists, initial encounter

• T44.5X6D - Underdosing of predominantly beta-adrenoreceptor agonists, subsequent encounter

• T44.5X6S - Underdosing of predominantly beta-adrenoreceptor agonists, sequela

• T44.6X5A - Adverse effect of alpha-adrenoreceptor antagonists, initial encounter

• T44.6X5D - Adverse effect of alpha-adrenoreceptor antagonists, subsequent encounter

• T44.6X5S - Adverse effect of alpha-adrenoreceptor antagonists, sequela

• T44.6X6A - Underdosing of alpha-adrenoreceptor antagonists, initial encounter

• T44.6X6D - Underdosing of alpha-adrenoreceptor antagonists, subsequent encounter

• T44.6X6S - Underdosing of alpha-adrenoreceptor antagonists, sequela

• T44.7X5A - Adverse effect of beta-adrenoreceptor antagonists, initial encounter

• T44.7X5D - Adverse effect of beta-adrenoreceptor antagonists, subsequent encounter

• T44.7X5S - Adverse effect of beta-adrenoreceptor antagonists, sequela

• T44.7X6A - Underdosing of beta-adrenoreceptor antagonists, initial encounter

• T44.7X6D - Underdosing of beta-adrenoreceptor antagonists, subsequent encounter

• T44.7X6S - Underdosing of beta-adrenoreceptor antagonists, sequela

• T44.8X5A - Adverse effect of centrally-acting and adrenergic-neuron-blocking agents, initial encounter

• T44.8X5D - Adverse effect of centrally-acting and adrenergic-neuron-blocking agents, subsequent encounter

• T44.8X5S - Adverse effect of centrally-acting and adrenergic-neuron-blocking agents, sequela

• T44.8X6A - Underdosing of centrally-acting and adrenergic-neuron-blocking agents, initial encounter

• T44.8X6D - Underdosing of centrally-acting and adrenergic-neuron-blocking agents, subsequent encounter

• T44.8X6S - Underdosing of centrally-acting and adrenergic-neuron-blocking agents, sequela

• T44.905A - Adverse effect of unspecified drugs primarily affecting the autonomic nervous system, initial encounter

• T44.905D - Adverse effect of unspecified drugs primarily affecting the autonomic nervous system, subsequent encounter

• T44.905S - Adverse effect of unspecified drugs primarily affecting the autonomic nervous system, sequela

• T44.906A - Underdosing of unspecified drugs primarily affecting the autonomic nervous system, initial encounter

• T44.906D - Underdosing of unspecified drugs primarily affecting the autonomic nervous system, subsequent encounter

• T44.906S - Underdosing of unspecified drugs primarily affecting the autonomic nervous system, sequela

• T44.995A - Adverse effect of other drug primarily affecting the autonomic nervous system, initial encounter

• T44.995D - Adverse effect of other drug primarily affecting the autonomic nervous system, subsequent encounter

• T44.995S - Adverse effect of other drug primarily affecting the autonomic nervous system, sequela

• T44.996A - Underdosing of other drug primarily affecting the autonomic nervous system, initial encounter

• T44.996D - Underdosing of other drug primarily affecting the autonomic nervous system, subsequent encounter

• T44.996S - Underdosing of other drug primarily affecting the autonomic nervous system, sequela

Poisoning by, adverse effect of and underdosing of primarily systemic and hematological agents, not elsewhere classified (T45)

• T45.0X5A - Adverse effect of antiallergic and antiemetic drugs, initial encounter

• T45.0X5D - Adverse effect of antiallergic and antiemetic drugs, subsequent encounter

• T45.0X5S - Adverse effect of antiallergic and antiemetic drugs, sequela

• T45.0X6A - Underdosing of antiallergic and antiemetic drugs, initial encounter

• T45.0X6D - Underdosing of antiallergic and antiemetic drugs, subsequent encounter

• T45.0X6S - Underdosing of antiallergic and antiemetic drugs, sequela

• T45.1X5A - Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter

• T45.1X5D - Adverse effect of antineoplastic and immunosuppressive drugs, subsequent encounter

• T45.1X5S - Adverse effect of antineoplastic and immunosuppressive drugs, sequela

• T45.1X6A - Underdosing of antineoplastic and immunosuppressive drugs, initial encounter

• T45.1X6D - Underdosing of antineoplastic and immunosuppressive drugs, subsequent encounter

• T45.1X6S - Underdosing of antineoplastic and immunosuppressive drugs, sequela

• T45.2X5A - Adverse effect of vitamins, initial encounter

• T45.2X5D - Adverse effect of vitamins, subsequent encounter

• T45.2X5S - Adverse effect of vitamins, sequela

• T45.2X6A - Underdosing of vitamins, initial encounter

• T45.2X6D - Underdosing of vitamins, subsequent encounter

• T45.2X6S - Underdosing of vitamins, sequela

• T45.3X5A - Adverse effect of enzymes, initial encounter

• T45.3X5D - Adverse effect of enzymes, subsequent encounter

• T45.3X5S - Adverse effect of enzymes, sequela

• T45.3X6A - Underdosing of enzymes, initial encounter

• T45.3X6D - Underdosing of enzymes, subsequent encounter

• T45.3X6S - Underdosing of enzymes, sequela

• T45.4X5A - Adverse effect of iron and its compounds, initial encounter

• T45.4X5D - Adverse effect of iron and its compounds, subsequent encounter

• T45.4X5S - Adverse effect of iron and its compounds, sequela

• T45.4X6A - Underdosing of iron and its compounds, initial encounter

• T45.4X6D - Underdosing of iron and its compounds, subsequent encounter

• T45.4X6S - Underdosing of iron and its compounds, sequela

• T45.515A - Adverse effect of anticoagulants, initial encounter

• T45.515D - Adverse effect of anticoagulants, subsequent encounter

• T45.515S - Adverse effect of anticoagulants, sequela

• T45.516A - Underdosing of anticoagulants, initial encounter

• T45.516D - Underdosing of anticoagulants, subsequent encounter

• T45.516S - Underdosing of anticoagulants, sequela

• T45.525A - Adverse effect of antithrombotic drugs, initial encounter

• T45.525D - Adverse effect of antithrombotic drugs, subsequent encounter

• T45.525S - Adverse effect of antithrombotic drugs, sequela

• T45.526A - Underdosing of antithrombotic drugs, initial encounter

• T45.526D - Underdosing of antithrombotic drugs, subsequent encounter

• T45.526S - Underdosing of antithrombotic drugs, sequela

• T45.605A - Adverse effect of unspecified fibrinolysis-affecting drugs, initial encounter

• T45.605D - Adverse effect of unspecified fibrinolysis-affecting drugs, subsequent encounter

• T45.605S - Adverse effect of unspecified fibrinolysis-affecting drugs, sequela

• T45.606A - Underdosing of unspecified fibrinolysis-affecting drugs, initial encounter

• T45.606D - Underdosing of unspecified fibrinolysis-affecting drugs, subsequent encounter

• T45.606S - Underdosing of unspecified fibrinolysis-affecting drugs, sequela

• T45.615A - Adverse effect of thrombolytic drugs, initial encounter

• T45.615D - Adverse effect of thrombolytic drugs, subsequent encounter

• T45.615S - Adverse effect of thrombolytic drugs, sequela

• T45.616A - Underdosing of thrombolytic drugs, initial encounter

• T45.616D - Underdosing of thrombolytic drugs, subsequent encounter

• T45.616S - Underdosing of thrombolytic drugs, sequela

• T45.625A - Adverse effect of hemostatic drug, initial encounter

• T45.625D - Adverse effect of hemostatic drug, subsequent encounter

• T45.625S - Adverse effect of hemostatic drug, sequela

• T45.626A - Underdosing of hemostatic drugs, initial encounter

• T45.626D - Underdosing of hemostatic drugs, subsequent encounter

• T45.626S - Underdosing of hemostatic drugs, sequela

• T45.695A - Adverse effect of other fibrinolysis-affecting drugs, initial encounter

• T45.695D - Adverse effect of other fibrinolysis-affecting drugs, subsequent encounter

• T45.695S - Adverse effect of other fibrinolysis-affecting drugs, sequela

• T45.696A - Underdosing of other fibrinolysis-affecting drugs, initial encounter

• T45.696D - Underdosing of other fibrinolysis-affecting drugs, subsequent encounter

• T45.696S - Underdosing of other fibrinolysis-affecting drugs, sequela

• T45.7X5A - Adverse effect of anticoagulant antagonists, vitamin K and other coagulants, initial encounter

• T45.7X5D - Adverse effect of anticoagulant antagonists, vitamin K and other coagulants, subsequent encounter

• T45.7X5S - Adverse effect of anticoagulant antagonists, vitamin K and other coagulants, sequela

• T45.7X6A - Underdosing of anticoagulant antagonist, vitamin K and other coagulants, initial encounter

• T45.7X6D - Underdosing of anticoagulant antagonist, vitamin K and other coagulants, subsequent encounter

• T45.7X6S - Underdosing of anticoagulant antagonist, vitamin K and other coagulants, sequela

• T45.8X5A - Adverse effect of other primarily systemic and hematological agents, initial encounter

• T45.8X5D - Adverse effect of other primarily systemic and hematological agents, subsequent encounter

• T45.8X5S - Adverse effect of other primarily systemic and hematological agents, sequela

• T45.8X6A - Underdosing of other primarily systemic and hematological agents, initial encounter

• T45.8X6D - Underdosing of other primarily systemic and hematological agents, subsequent encounter

• T45.8X6S - Underdosing of other primarily systemic and hematological agents, sequela

• T45.95XA - Adverse effect of unspecified primarily systemic and hematological agent, initial encounter

• T45.95XD - Adverse effect of unspecified primarily systemic and hematological agent, subsequent encounter

• T45.95XS - Adverse effect of unspecified primarily systemic and hematological agent, sequela

• T45.96XA - Underdosing of unspecified primarily systemic and hematological agent, initial encounter

• T45.96XD - Underdosing of unspecified primarily systemic and hematological agent, subsequent encounter

• T45.96XS - Underdosing of unspecified primarily systemic and hematological agent, sequela

Poisoning by, adverse effect of and underdosing of agents primarily affecting the cardiovascular system (T46)

• T46.0X5A - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, initial encounter

• T46.0X5D - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, subsequent encounter

• T46.0X5S - Adverse effect of cardiac-stimulant glycosides and drugs of similar action, sequela

• T46.0X6A - Underdosing of cardiac-stimulant glycosides and drugs of similar action, initial encounter

• T46.0X6D - Underdosing of cardiac-stimulant glycosides and drugs of similar action, subsequent encounter

• T46.0X6S - Underdosing of cardiac-stimulant glycosides and drugs of similar action, sequela

• T46.1X5A - Adverse effect of calcium-channel blockers, initial encounter

• T46.1X5D - Adverse effect of calcium-channel blockers, subsequent encounter

• T46.1X5S - Adverse effect of calcium-channel blockers, sequela

• T46.1X6A - Underdosing of calcium-channel blockers, initial encounter

• T46.1X6D - Underdosing of calcium-channel blockers, subsequent encounter

• T46.1X6S - Underdosing of calcium-channel blockers, sequela

• T46.2X5A - Adverse effect of other antidysrhythmic drugs, initial encounter

• T46.2X5D - Adverse effect of other antidysrhythmic drugs, subsequent encounter

• T46.2X5S - Adverse effect of other antidysrhythmic drugs, sequela

• T46.2X6A - Underdosing of other antidysrhythmic drugs, initial encounter

• T46.2X6D - Underdosing of other antidysrhythmic drugs, subsequent encounter

• T46.2X6S - Underdosing of other antidysrhythmic drugs, sequela

• T46.3X5A - Adverse effect of coronary vasodilators, initial encounter

• T46.3X5D - Adverse effect of coronary vasodilators, subsequent encounter

• T46.3X5S - Adverse effect of coronary vasodilators, sequela

• T46.3X6A - Underdosing of coronary vasodilators, initial encounter

• T46.3X6D - Underdosing of coronary vasodilators, subsequent encounter

• T46.3X6S - Underdosing of coronary vasodilators, sequela

• T46.4X5A - Adverse effect of angiotensin-converting-enzyme inhibitors, initial encounter

• T46.4X5D - Adverse effect of angiotensin-converting-enzyme inhibitors, subsequent encounter

• T46.4X5S - Adverse effect of angiotensin-converting-enzyme inhibitors, sequela

• T46.4X6A - Underdosing of angiotensin-converting-enzyme inhibitors, initial encounter

• T46.4X6D - Underdosing of angiotensin-converting-enzyme inhibitors, subsequent encounter

• T46.4X6S - Underdosing of angiotensin-converting-enzyme inhibitors, sequela

• T46.5X5A - Adverse effect of other antihypertensive drugs, initial encounter

• T46.5X5D - Adverse effect of other antihypertensive drugs, subsequent encounter

• T46.5X5S - Adverse effect of other antihypertensive drugs, sequela

• T46.5X6A - Underdosing of other antihypertensive drugs, initial encounter

• T46.5X6D - Underdosing of other antihypertensive drugs, subsequent encounter

• T46.5X6S - Underdosing of other antihypertensive drugs, sequela

• T46.6X5A - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter

• T46.6X5D - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, subsequent encounter

• T46.6X5S - Adverse effect of antihyperlipidemic and antiarteriosclerotic drugs, sequela

• T46.6X6A - Underdosing of antihyperlipidemic and antiarteriosclerotic drugs, initial encounter

• T46.6X6D - Underdosing of antihyperlipidemic and antiarteriosclerotic drugs, subsequent encounter

• T46.6X6S - Underdosing of antihyperlipidemic and antiarteriosclerotic drugs, sequela

• T46.7X5A - Adverse effect of peripheral vasodilators, initial encounter

• T46.7X5D - Adverse effect of peripheral vasodilators, subsequent encounter

• T46.7X5S - Adverse effect of peripheral vasodilators, sequela

• T46.7X6A - Underdosing of peripheral vasodilators, initial encounter

• T46.7X6D - Underdosing of peripheral vasodilators, subsequent encounter

• T46.7X6S - Underdosing of peripheral vasodilators, sequela

• T46.8X5A - Adverse effect of antivaricose drugs, including sclerosing agents, initial encounter

• T46.8X5D - Adverse effect of antivaricose drugs, including sclerosing agents, subsequent encounter

• T46.8X5S - Adverse effect of antivaricose drugs, including sclerosing agents, sequela

• T46.8X6A - Underdosing of antivaricose drugs, including sclerosing agents, initial encounter

• T46.8X6D - Underdosing of antivaricose drugs, including sclerosing agents, subsequent encounter

• T46.8X6S - Underdosing of antivaricose drugs, including sclerosing agents, sequela

• T46.905A - Adverse effect of unspecified agents primarily affecting the cardiovascular system, initial encounter

• T46.905D - Adverse effect of unspecified agents primarily affecting the cardiovascular system, subsequent encounter

• T46.905S - Adverse effect of unspecified agents primarily affecting the cardiovascular system, sequela

• T46.906A - Underdosing of unspecified agents primarily affecting the cardiovascular system, initial encounter

• T46.906D - Underdosing of unspecified agents primarily affecting the cardiovascular system, subsequent encounter

• T46.906S - Underdosing of unspecified agents primarily affecting the cardiovascular system, sequela

• T46.995A - Adverse effect of other agents primarily affecting the cardiovascular system, initial encounter

• T46.995D - Adverse effect of other agents primarily affecting the cardiovascular system, subsequent encounter

• T46.995S - Adverse effect of other agents primarily affecting the cardiovascular system, sequela

• T46.996A - Underdosing of other agents primarily affecting the cardiovascular system, initial encounter

• T46.996D - Underdosing of other agents primarily affecting the cardiovascular system, subsequent encounter

• T46.996S - Underdosing of other agents primarily affecting the cardiovascular system, sequela

Poisoning by, adverse effect of and underdosing of agents primarily affecting the gastrointestinal system (T47)

• T47.0X5A - Adverse effect of histamine H2-receptor blockers, initial encounter

• T47.0X5D - Adverse effect of histamine H2-receptor blockers, subsequent encounter

• T47.0X5S - Adverse effect of histamine H2-receptor blockers, sequela

• T47.0X6A - Underdosing of histamine H2-receptor blockers, initial encounter

• T47.0X6D - Underdosing of histamine H2-receptor blockers, subsequent encounter

• T47.0X6S - Underdosing of histamine H2-receptor blockers, sequela

• T47.1X5A - Adverse effect of other antacids and anti-gastric-secretion drugs, initial encounter

• T47.1X5D - Adverse effect of other antacids and anti-gastric-secretion drugs, subsequent encounter

• T47.1X5S - Adverse effect of other antacids and anti-gastric-secretion drugs, sequela

• T47.1X6A - Underdosing of other antacids and anti-gastric-secretion drugs, initial encounter

• T47.1X6D - Underdosing of other antacids and anti-gastric-secretion drugs, subsequent encounter

• T47.1X6S - Underdosing of other antacids and anti-gastric-secretion drugs, sequela

• T47.2X5A - Adverse effect of stimulant laxatives, initial encounter

• T47.2X5D - Adverse effect of stimulant laxatives, subsequent encounter

• T47.2X5S - Adverse effect of stimulant laxatives, sequela

• T47.2X6A - Underdosing of stimulant laxatives, initial encounter

• T47.2X6D - Underdosing of stimulant laxatives, subsequent encounter

• T47.2X6S - Underdosing of stimulant laxatives, sequela

• T47.3X5A - Adverse effect of saline and osmotic laxatives, initial encounter

• T47.3X5D - Adverse effect of saline and osmotic laxatives, subsequent encounter

• T47.3X5S - Adverse effect of saline and osmotic laxatives, sequela

• T47.3X6A - Underdosing of saline and osmotic laxatives, initial encounter

• T47.3X6D - Underdosing of saline and osmotic laxatives, subsequent encounter

• T47.3X6S - Underdosing of saline and osmotic laxatives, sequela

• T47.4X5A - Adverse effect of other laxatives, initial encounter

• T47.4X5D - Adverse effect of other laxatives, subsequent encounter

• T47.4X5S - Adverse effect of other laxatives, sequela

• T47.4X6A - Underdosing of other laxatives, initial encounter

• T47.4X6D - Underdosing of other laxatives, subsequent encounter

• T47.4X6S - Underdosing of other laxatives, sequela

• T47.5X5A - Adverse effect of digestants, initial encounter

• T47.5X5D - Adverse effect of digestants, subsequent encounter

• T47.5X5S - Adverse effect of digestants, sequela

• T47.5X6A - Underdosing of digestants, initial encounter

• T47.5X6D - Underdosing of digestants, subsequent encounter

• T47.5X6S - Underdosing of digestants, sequela

• T47.6X5A - Adverse effect of antidiarrheal drugs, initial encounter

• T47.6X5D - Adverse effect of antidiarrheal drugs, subsequent encounter

• T47.6X5S - Adverse effect of antidiarrheal drugs, sequela

• T47.6X6A - Underdosing of antidiarrheal drugs, initial encounter

• T47.6X6D - Underdosing of antidiarrheal drugs, subsequent encounter

• T47.6X6S - Underdosing of antidiarrheal drugs, sequela

• T47.7X5A - Adverse effect of emetics, initial encounter

• T47.7X5D - Adverse effect of emetics, subsequent encounter

• T47.7X5S - Adverse effect of emetics, sequela

• T47.7X6A - Underdosing of emetics, initial encounter

• T47.7X6D - Underdosing of emetics, subsequent encounter

• T47.7X6S - Underdosing of emetics, sequela

• T47.8X5A - Adverse effect of other agents primarily affecting gastrointestinal system, initial encounter

• T47.8X5D - Adverse effect of other agents primarily affecting gastrointestinal system, subsequent encounter

• T47.8X5S - Adverse effect of other agents primarily affecting gastrointestinal system, sequela

• T47.8X6A - Underdosing of other agents primarily affecting gastrointestinal system, initial encounter

• T47.8X6D - Underdosing of other agents primarily affecting gastrointestinal system, subsequent encounter

• T47.8X6S - Underdosing of other agents primarily affecting gastrointestinal system, sequela

• T47.95XA - Adverse effect of unspecified agents primarily affecting the gastrointestinal system, initial encounter

• T47.95XD - Adverse effect of unspecified agents primarily affecting the gastrointestinal system, subsequent encounter

• T47.95XS - Adverse effect of unspecified agents primarily affecting the gastrointestinal system, sequela

• T47.96XA - Underdosing of unspecified agents primarily affecting the gastrointestinal system, initial encounter

• T47.96XD - Underdosing of unspecified agents primarily affecting the gastrointestinal system, subsequent encounter

• T47.96XS - Underdosing of unspecified agents primarily affecting the gastrointestinal system, sequela

Poisoning by, adverse effect of and underdosing of agents primarily acting on smooth and skeletal muscles and the respiratory system (T48)

• T48.0X5A - Adverse effect of oxytocic drugs, initial encounter

• T48.0X5D - Adverse effect of oxytocic drugs, subsequent encounter

• T48.0X5S - Adverse effect of oxytocic drugs, sequela

• T48.0X6A - Underdosing of oxytocic drugs, initial encounter

• T48.0X6D - Underdosing of oxytocic drugs, subsequent encounter

• T48.0X6S - Underdosing of oxytocic drugs, sequela

• T48.1X5A - Adverse effect of skeletal muscle relaxants [neuromuscular blocking agents], initial encounter

• T48.1X5D - Adverse effect of skeletal muscle relaxants [neuromuscular blocking agents], subsequent encounter

• T48.1X5S - Adverse effect of skeletal muscle relaxants [neuromuscular blocking agents], sequela

• T48.1X6A - Underdosing of skeletal muscle relaxants [neuromuscular blocking agents], initial encounter

• T48.1X6D - Underdosing of skeletal muscle relaxants [neuromuscular blocking agents], subsequent encounter

• T48.1X6S - Underdosing of skeletal muscle relaxants [neuromuscular blocking agents], sequela

• T48.205A - Adverse effect of unspecified drugs acting on muscles, initial encounter

• T48.205D - Adverse effect of unspecified drugs acting on muscles, subsequent encounter

• T48.205S - Adverse effect of unspecified drugs acting on muscles, sequela

• T48.206A - Underdosing of unspecified drugs acting on muscles, initial encounter

• T48.206D - Underdosing of unspecified drugs acting on muscles, subsequent encounter

• T48.206S - Underdosing of unspecified drugs acting on muscles, sequela

• T48.295A - Adverse effect of other drugs acting on muscles, initial encounter

• T48.295D - Adverse effect of other drugs acting on muscles, subsequent encounter

• T48.295S - Adverse effect of other drugs acting on muscles, sequela

• T48.296A - Underdosing of other drugs acting on muscles, initial encounter

• T48.296D - Underdosing of other drugs acting on muscles, subsequent encounter

• T48.296S - Underdosing of other drugs acting on muscles, sequela

• T48.3X5A - Adverse effect of antitussives, initial encounter

• T48.3X5D - Adverse effect of antitussives, subsequent encounter

• T48.3X5S - Adverse effect of antitussives, sequela

• T48.3X6A - Underdosing of antitussives, initial encounter

• T48.3X6D - Underdosing of antitussives, subsequent encounter

• T48.3X6S - Underdosing of antitussives, sequela

• T48.4X5A - Adverse effect of expectorants, initial encounter

• T48.4X5D - Adverse effect of expectorants, subsequent encounter

• T48.4X5S - Adverse effect of expectorants, sequela

• T48.4X6A - Underdosing of expectorants, initial encounter

• T48.4X6D - Underdosing of expectorants, subsequent encounter

• T48.4X6S - Underdosing of expectorants, sequela

• T48.5X5A - Adverse effect of other anti-common-cold drugs, initial encounter

• T48.5X5D - Adverse effect of other anti-common-cold drugs, subsequent encounter

• T48.5X5S - Adverse effect of other anti-common-cold drugs, sequela

• T48.5X6A - Underdosing of other anti-common-cold drugs, initial encounter

• T48.5X6D - Underdosing of other anti-common-cold drugs, subsequent encounter

• T48.5X6S - Underdosing of other anti-common-cold drugs, sequela

• T48.6X5A - Adverse effect of antiasthmatics, initial encounter

• T48.6X5D - Adverse effect of antiasthmatics, subsequent encounter

• T48.6X5S - Adverse effect of antiasthmatics, sequela

• T48.6X6A - Underdosing of antiasthmatics, initial encounter

• T48.6X6D - Underdosing of antiasthmatics, subsequent encounter

• T48.6X6S - Underdosing of antiasthmatics, sequela

• T48.905A - Adverse effect of unspecified agents primarily acting on the respiratory system, initial encounter

• T48.905D - Adverse effect of unspecified agents primarily acting on the respiratory system, subsequent encounter

• T48.905S - Adverse effect of unspecified agents primarily acting on the respiratory system, sequela

• T48.906A - Underdosing of unspecified agents primarily acting on the respiratory system, initial encounter

• T48.906D - Underdosing of unspecified agents primarily acting on the respiratory system, subsequent encounter

• T48.906S - Underdosing of unspecified agents primarily acting on the respiratory system, sequela

• T48.995A - Adverse effect of other agents primarily acting on the respiratory system, initial encounter

• T48.995D - Adverse effect of other agents primarily acting on the respiratory system, subsequent encounter

• T48.995S - Adverse effect of other agents primarily acting on the respiratory system, sequela

• T48.996A - Underdosing of other agents primarily acting on the respiratory system, initial encounter

• T48.996D - Underdosing of other agents primarily acting on the respiratory system, subsequent encounter

• T48.996S - Underdosing of other agents primarily acting on the respiratory system, sequela

Poisoning by, adverse effect of and underdosing of topical agents primarily affecting skin and mucous membrane and by ophthalmological, otorhinorlaryngological and dental drugs (T49)

• T49.0X5A - Adverse effect of local antifungal, anti-infective and anti-inflammatory drugs, initial encounter

• T49.0X5D - Adverse effect of local antifungal, anti-infective and anti-inflammatory drugs, subsequent encounter

• T49.0X5S - Adverse effect of local antifungal, anti-infective and anti-inflammatory drugs, sequela

• T49.0X6A - Underdosing of local antifungal, anti-infective and anti-inflammatory drugs, initial encounter

• T49.0X6D - Underdosing of local antifungal, anti-infective and anti-inflammatory drugs, subsequent encounter

• T49.0X6S - Underdosing of local antifungal, anti-infective and anti-inflammatory drugs, sequela

• T49.1X5A - Adverse effect of antipruritics, initial encounter

• T49.1X5D - Adverse effect of antipruritics, subsequent encounter

• T49.1X5S - Adverse effect of antipruritics, sequela

• T49.1X6A - Underdosing of antipruritics, initial encounter

• T49.1X6D - Underdosing of antipruritics, subsequent encounter

• T49.1X6S - Underdosing of antipruritics, sequela

• T49.2X5A - Adverse effect of local astringents and local detergents, initial encounter

• T49.2X5D - Adverse effect of local astringents and local detergents, subsequent encounter

• T49.2X5S - Adverse effect of local astringents and local detergents, sequela

• T49.2X6A - Underdosing of local astringents and local detergents, initial encounter

• T49.2X6D - Underdosing of local astringents and local detergents, subsequent encounter

• T49.2X6S - Underdosing of local astringents and local detergents, sequela

• T49.3X5A - Adverse effect of emollients, demulcents and protectants, initial encounter

• T49.3X5D - Adverse effect of emollients, demulcents and protectants, subsequent encounter

• T49.3X5S - Adverse effect of emollients, demulcents and protectants, sequela

• T49.3X6A - Underdosing of emollients, demulcents and protectants, initial encounter

• T49.3X6D - Underdosing of emollients, demulcents and protectants, subsequent encounter

• T49.3X6S - Underdosing of emollients, demulcents and protectants, sequela

• T49.4X5A - Adverse effect of keratolytics, keratoplastics, and other hair treatment drugs and preparations, initial encounter

• T49.4X5D - Adverse effect of keratolytics, keratoplastics, and other hair treatment drugs and preparations, subsequent encounter

• T49.4X5S - Adverse effect of keratolytics, keratoplastics, and other hair treatment drugs and preparations, sequela

• T49.4X6A - Underdosing of keratolytics, keratoplastics, and other hair treatment drugs and preparations, initial encounter

• T49.4X6D - Underdosing of keratolytics, keratoplastics, and other hair treatment drugs and preparations, subsequent encounter

• T49.4X6S - Underdosing of keratolytics, keratoplastics, and other hair treatment drugs and preparations, sequela

• T49.5X5A - Adverse effect of ophthalmological drugs and preparations, initial encounter

• T49.5X5D - Adverse effect of ophthalmological drugs and preparations, subsequent encounter

• T49.5X5S - Adverse effect of ophthalmological drugs and preparations, sequela

• T49.5X6A - Underdosing of ophthalmological drugs and preparations, initial encounter

• T49.5X6D - Underdosing of ophthalmological drugs and preparations, subsequent encounter

• T49.5X6S - Underdosing of ophthalmological drugs and preparations, sequela

• T49.6X5A - Adverse effect of otorhinolaryngological drugs and preparations, initial encounter

• T49.6X5D - Adverse effect of otorhinolaryngological drugs and preparations, subsequent encounter

• T49.6X5S - Adverse effect of otorhinolaryngological drugs and preparations, sequela

• T49.6X6A - Underdosing of otorhinolaryngological drugs and preparations, initial encounter

• T49.6X6D - Underdosing of otorhinolaryngological drugs and preparations, subsequent encounter

• T49.6X6S - Underdosing of otorhinolaryngological drugs and preparations, sequela

• T49.7X5A - Adverse effect of dental drugs, topically applied, initial encounter

• T49.7X5D - Adverse effect of dental drugs, topically applied, subsequent encounter

• T49.7X5S - Adverse effect of dental drugs, topically applied, sequela

• T49.7X6A - Underdosing of dental drugs, topically applied, initial encounter

• T49.7X6D - Underdosing of dental drugs, topically applied, subsequent encounter

• T49.7X6S - Underdosing of dental drugs, topically applied, sequela

• T49.8X5A - Adverse effect of other topical agents, initial encounter

• T49.8X5D - Adverse effect of other topical agents, subsequent encounter

• T49.8X5S - Adverse effect of other topical agents, sequela

• T49.8X6A - Underdosing of other topical agents, initial encounter

• T49.8X6D - Underdosing of other topical agents, subsequent encounter

• T49.8X6S - Underdosing of other topical agents, sequela

• T49.95XA - Adverse effect of unspecified topical agent, initial encounter

• T49.95XD - Adverse effect of unspecified topical agent, subsequent encounter

• T49.95XS - Adverse effect of unspecified topical agent, sequela

• T49.96XA - Underdosing of unspecified topical agent, initial encounter

• T49.96XD - Underdosing of unspecified topical agent, subsequent encounter

• T49.96XS - Underdosing of unspecified topical agent, sequela

Poisoning by, adverse effect of and underdosing of diuretics and other and unspecified drugs, medicaments and biological substances (T50)

• T50.0X5A - Adverse effect of mineralocorticoids and their antagonists, initial encounter

• T50.0X5D - Adverse effect of mineralocorticoids and their antagonists, subsequent encounter

• T50.0X5S - Adverse effect of mineralocorticoids and their antagonists, sequela

• T50.0X6A - Underdosing of mineralocorticoids and their antagonists, initial encounter

• T50.0X6D - Underdosing of mineralocorticoids and their antagonists, subsequent encounter

• T50.0X6S - Underdosing of mineralocorticoids and their antagonists, sequela

• T50.1X5A - Adverse effect of loop [high-ceiling] diuretics, initial encounter

• T50.1X5D - Adverse effect of loop [high-ceiling] diuretics, subsequent encounter

• T50.1X5S - Adverse effect of loop [high-ceiling] diuretics, sequela

• T50.1X6A - Underdosing of loop [high-ceiling] diuretics, initial encounter

• T50.1X6D - Underdosing of loop [high-ceiling] diuretics, subsequent encounter

• T50.1X6S - Underdosing of loop [high-ceiling] diuretics, sequela

• T50.2X5A - Adverse effect of carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, initial encounter

• T50.2X5D - Adverse effect of carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, subsequent encounter

• T50.2X5S - Adverse effect of carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, sequela

• T50.2X6A - Underdosing of carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, initial encounter

• T50.2X6D - Underdosing of carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, subsequent encounter

• T50.2X6S - Underdosing of carbonic-anhydrase inhibitors, benzothiadiazides and other diuretics, sequela

• T50.3X5A - Adverse effect of electrolytic, caloric and water-balance agents, initial encounter

• T50.3X5D - Adverse effect of electrolytic, caloric and water-balance agents, subsequent encounter

• T50.3X5S - Adverse effect of electrolytic, caloric and water-balance agents, sequela

• T50.3X6A - Underdosing of electrolytic, caloric and water-balance agents, initial encounter

• T50.3X6D - Underdosing of electrolytic, caloric and water-balance agents, subsequent encounter

• T50.3X6S - Underdosing of electrolytic, caloric and water-balance agents, sequela

• T50.4X5A - Adverse effect of drugs affecting uric acid metabolism, initial encounter

• T50.4X5D - Adverse effect of drugs affecting uric acid metabolism, subsequent encounter

• T50.4X5S - Adverse effect of drugs affecting uric acid metabolism, sequela

• T50.4X6A - Underdosing of drugs affecting uric acid metabolism, initial encounter

• T50.4X6D - Underdosing of drugs affecting uric acid metabolism, subsequent encounter

• T50.4X6S - Underdosing of drugs affecting uric acid metabolism, sequela

• T50.5X5A - Adverse effect of appetite depressants, initial encounter

• T50.5X5D - Adverse effect of appetite depressants, subsequent encounter

• T50.5X5S - Adverse effect of appetite depressants, sequela

• T50.5X6A - Underdosing of appetite depressants, initial encounter

• T50.5X6D - Underdosing of appetite depressants, subsequent encounter

• T50.5X6S - Underdosing of appetite depressants, sequela

• T50.6X5A - Adverse effect of antidotes and chelating agents, initial encounter

• T50.6X5D - Adverse effect of antidotes and chelating agents, subsequent encounter

• T50.6X5S - Adverse effect of antidotes and chelating agents, sequela

• T50.6X6A - Underdosing of antidotes and chelating agents, initial encounter

• T50.6X6D - Underdosing of antidotes and chelating agents, subsequent encounter

• T50.6X6S - Underdosing of antidotes and chelating agents, sequela

• T50.7X5A - Adverse effect of analeptics and opioid receptor antagonists, initial encounter

• T50.7X5D - Adverse effect of analeptics and opioid receptor antagonists, subsequent encounter

• T50.7X5S - Adverse effect of analeptics and opioid receptor antagonists, sequela

• T50.7X6A - Underdosing of analeptics and opioid receptor antagonists, initial encounter

• T50.7X6D - Underdosing of analeptics and opioid receptor antagonists, subsequent encounter

• T50.7X6S - Underdosing of analeptics and opioid receptor antagonists, sequela

• T50.8X5A - Adverse effect of diagnostic agents, initial encounter

• T50.8X5D - Adverse effect of diagnostic agents, subsequent encounter

• T50.8X5S - Adverse effect of diagnostic agents, sequela

• T50.8X6A - Underdosing of diagnostic agents, initial encounter

• T50.8X6D - Underdosing of diagnostic agents, subsequent encounter

• T50.8X6S - Underdosing of diagnostic agents, sequela

• T50.915A - Adverse effect of multiple unspecified drugs, medicaments and biological substances, initial encounter

• T50.915D - Adverse effect of multiple unspecified drugs, medicaments and biological substances, subsequent encounter

• T50.915S - Adverse effect of multiple unspecified drugs, medicaments and biological substances, sequela

• T50.916A - Underdosing of multiple unspecified drugs, medicaments and biological substances, initial encounter

• T50.916D - Underdosing of multiple unspecified drugs, medicaments and biological substances, subsequent encounter

• T50.916S - Underdosing of multiple unspecified drugs, medicaments and biological substances, sequela

• T50.A15A - Adverse effect of pertussis vaccine, including combinations with a pertussis component, initial encounter

• T50.A15D - Adverse effect of pertussis vaccine, including combinations with a pertussis component, subsequent encounter

• T50.A15S - Adverse effect of pertussis vaccine, including combinations with a pertussis component, sequela

• T50.A16A - Underdosing of pertussis vaccine, including combinations with a pertussis component, initial encounter

• T50.A16D - Underdosing of pertussis vaccine, including combinations with a pertussis component, subsequent encounter

• T50.A16S - Underdosing of pertussis vaccine, including combinations with a pertussis component, sequela

• T50.A25A - Adverse effect of mixed bacterial vaccines without a pertussis component, initial encounter

• T50.A25D - Adverse effect of mixed bacterial vaccines without a pertussis component, subsequent encounter

• T50.A25S - Adverse effect of mixed bacterial vaccines without a pertussis component, sequela

• T50.A26A - Underdosing of mixed bacterial vaccines without a pertussis component, initial encounter

• T50.A26D - Underdosing of mixed bacterial vaccines without a pertussis component, subsequent encounter

• T50.A26S - Underdosing of mixed bacterial vaccines without a pertussis component, sequela

• T50.A95A - Adverse effect of other bacterial vaccines, initial encounter

• T50.A95D - Adverse effect of other bacterial vaccines, subsequent encounter

• T50.A95S - Adverse effect of other bacterial vaccines, sequela

• T50.A96A - Underdosing of other bacterial vaccines, initial encounter

• T50.A96D - Underdosing of other bacterial vaccines, subsequent encounter

• T50.A96S - Underdosing of other bacterial vaccines, sequela

• T50.B15A - Adverse effect of smallpox vaccines, initial encounter

• T50.B15D - Adverse effect of smallpox vaccines, subsequent encounter

• T50.B15S - Adverse effect of smallpox vaccines, sequela

• T50.B16A - Underdosing of smallpox vaccines, initial encounter

• T50.B16D - Underdosing of smallpox vaccines, subsequent encounter

• T50.B16S - Underdosing of smallpox vaccines, sequela

• T50.B95A - Adverse effect of other viral vaccines, initial encounter

• T50.B95D - Adverse effect of other viral vaccines, subsequent encounter

• T50.B95S - Adverse effect of other viral vaccines, sequela

• T50.B96A - Underdosing of other viral vaccines, initial encounter

• T50.B96D - Underdosing of other viral vaccines, subsequent encounter

• T50.B96S - Underdosing of other viral vaccines, sequela

• T50.Z15A - Adverse effect of immunoglobulin, initial encounter

• T50.Z15D - Adverse effect of immunoglobulin, subsequent encounter

• T50.Z15S - Adverse effect of immunoglobulin, sequela

• T50.Z16A - Underdosing of immunoglobulin, initial encounter

• T50.Z16D - Underdosing of immunoglobulin, subsequent encounter

• T50.Z16S - Underdosing of immunoglobulin, sequela

• T50.Z95A - Adverse effect of other vaccines and biological substances, initial encounter

• T50.Z95D - Adverse effect of other vaccines and biological substances, subsequent encounter

• T50.Z95S - Adverse effect of other vaccines and biological substances, sequela

• T50.Z96A - Underdosing of other vaccines and biological substances, initial encounter

• T50.Z96D - Underdosing of other vaccines and biological substances, subsequent encounter

• T50.Z96S - Underdosing of other vaccines and biological substances, sequela

Complications of procedures, not elsewhere classified (T81)

• T81.12XA - Postprocedural septic shock, initial encounter

• T81.12XD - Postprocedural septic shock, subsequent encounter

• T81.12XS - Postprocedural septic shock, sequela

Encounter for general examination without complaint, suspected or reported diagnosis (Z00)

• Z00.00 - Encounter for general adult medical examination without abnormal findings

• Z00.01 - Encounter for general adult medical examination with abnormal findings

• Z00.110 - Health examination for newborn under 8 days old

• Z00.111 - Health examination for newborn 8 to 28 days old

• Z00.121 - Encounter for routine child health examination with abnormal findings

• Z00.129 - Encounter for routine child health examination without abnormal findings

• Z00.2 - Encounter for examination for period of rapid growth in childhood

• Z00.3 - Encounter for examination for adolescent development state

• Z00.5 - Encounter for examination of potential donor of organ and tissue

• Z00.70 - Encounter for examination for period of delayed growth in childhood without abnormal findings

• Z00.71 - Encounter for examination for period of delayed growth in childhood with abnormal findings

• Z00.8 - Encounter for other general examination

Encounter for other special examination without complaint, suspected or reported diagnosis (Z01)

• Z01.10 - Encounter for examination of ears and hearing without abnormal findings

• Z01.110 - Encounter for hearing examination following failed hearing screening

• Z01.118 - Encounter for examination of ears and hearing with other abnormal findings

• Z01.12 - Encounter for hearing conservation and treatment

• Z01.20 - Encounter for dental examination and cleaning without abnormal findings

• Z01.21 - Encounter for dental examination and cleaning with abnormal findings

• Z01.30 - Encounter for examination of blood pressure without abnormal findings

• Z01.31 - Encounter for examination of blood pressure with abnormal findings

• Z01.812 - Encounter for preprocedural laboratory examination

• Z01.818 - Encounter for other preprocedural examination

• Z01.82 - Encounter for allergy testing

• Z01.83 - Encounter for blood typing

• Z01.84 - Encounter for antibody response examination

• Z01.89 - Encounter for other specified special examinations

Encounter for administrative examination (Z02)

• Z02.0 - Encounter for examination for admission to educational institution

• Z02.2 - Encounter for examination for admission to residential institution

• Z02.4 - Encounter for examination for driving license

• Z02.5 - Encounter for examination for participation in sport

• Z02.6 - Encounter for examination for insurance purposes

• Z02.71 - Encounter for disability determination

• Z02.79 - Encounter for issue of other medical certificate

• Z02.82 - Encounter for adoption services

• Z02.84 - Encounter for child welfare exam

• Z02.89 - Encounter for other administrative examinations

• Z02.9 - Encounter for administrative examinations, unspecified

Encounter for medical observation for suspected diseases and conditions ruled out (Z03)

• Z03.71 - Encounter for suspected problem with amniotic cavity and membrane ruled out

• Z03.72 - Encounter for suspected placental problem ruled out

• Z03.73 - Encounter for suspected fetal anomaly ruled out

• Z03.74 - Encounter for suspected problem with fetal growth ruled out

• Z03.75 - Encounter for suspected cervical shortening ruled out

• Z03.79 - Encounter for other suspected maternal and fetal conditions ruled out

• Z03.821 - Encounter for observation for suspected ingested foreign body ruled out

• Z03.822 - Encounter for observation for suspected aspirated (inhaled) foreign body ruled out

• Z03.823 - Encounter for observation for suspected inserted (injected) foreign body ruled out

• Z03.83 - Encounter for observation for suspected conditions related to home physiologic monitoring device ruled out

Encounter for examination and observation for other reasons (Z04)

• Z04.9 - Encounter for examination and observation for unspecified reason

Encounter for follow-up examination after completed treatment for malignant neoplasm (Z08)

• Z08 - Encounter for follow-up examination after completed treatment for malignant neoplasm

Encounter for follow-up examination after completed treatment for conditions other than malignant neoplasm (Z09)

• Z09 - Encounter for follow-up examination after completed treatment for conditions other than malignant neoplasm

Encounter for screening for infectious and parasitic diseases (Z11)

• Z11.0 - Encounter for screening for intestinal infectious diseases

• Z11.1 - Encounter for screening for respiratory tuberculosis

• Z11.2 - Encounter for screening for other bacterial diseases

• Z11.3 - Encounter for screening for infections with a predominantly sexual mode of transmission

• Z11.4 - Encounter for screening for human immunodeficiency virus [HIV]

• Z11.51 - Encounter for screening for human papillomavirus (HPV)

• Z11.52 - Encounter for screening for COVID-19

• Z11.59 - Encounter for screening for other viral diseases

• Z11.6 - Encounter for screening for other protozoal diseases and helminthiases

• Z11.7 - Encounter for testing for latent tuberculosis infection

• Z11.8 - Encounter for screening for other infectious and parasitic diseases

• Z11.9 - Encounter for screening for infectious and parasitic diseases, unspecified

Encounter for screening for malignant neoplasms (Z12)

• Z12.0 - Encounter for screening for malignant neoplasm of stomach

• Z12.10 - Encounter for screening for malignant neoplasm of intestinal tract, unspecified

• Z12.11 - Encounter for screening for malignant neoplasm of colon

• Z12.12 - Encounter for screening for malignant neoplasm of rectum

• Z12.13 - Encounter for screening for malignant neoplasm of small intestine

• Z12.2 - Encounter for screening for malignant neoplasm of respiratory organs

• Z12.31 - Encounter for screening mammogram for malignant neoplasm of breast

• Z12.39 - Encounter for other screening for malignant neoplasm of breast

• Z12.4 - Encounter for screening for malignant neoplasm of cervix

• Z12.6 - Encounter for screening for malignant neoplasm of bladder

• Z12.71 - Encounter for screening for malignant neoplasm of testis

• Z12.72 - Encounter for screening for malignant neoplasm of vagina

• Z12.73 - Encounter for screening for malignant neoplasm of ovary

• Z12.79 - Encounter for screening for malignant neoplasm of other genitourinary organs

• Z12.81 - Encounter for screening for malignant neoplasm of oral cavity

• Z12.82 - Encounter for screening for malignant neoplasm of nervous system

• Z12.83 - Encounter for screening for malignant neoplasm of skin

• Z12.89 - Encounter for screening for malignant neoplasm of other sites

• Z12.9 - Encounter for screening for malignant neoplasm, site unspecified

Encounter for screening for other diseases and disorders (Z13)

• Z13.0 - Encounter for screening for diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism

• Z13.1 - Encounter for screening for diabetes mellitus

• Z13.21 - Encounter for screening for nutritional disorder

• Z13.220 - Encounter for screening for lipoid disorders

• Z13.228 - Encounter for screening for other metabolic disorders

• Z13.29 - Encounter for screening for other suspected endocrine disorder

• Z13.30 - Encounter for screening examination for mental health and behavioral disorders, unspecified

• Z13.31 - Encounter for screening for depression

• Z13.32 - Encounter for screening for maternal depression

• Z13.39 - Encounter for screening examination for other mental health and behavioral disorders

• Z13.40 - Encounter for screening for unspecified developmental delays

• Z13.41 - Encounter for autism screening

• Z13.42 - Encounter for screening for global developmental delays (milestones)

• Z13.49 - Encounter for screening for other developmental delays

• Z13.5 - Encounter for screening for eye and ear disorders

• Z13.6 - Encounter for screening for cardiovascular disorders

• Z13.71 - Encounter for nonprocreative screening for genetic disease carrier status

• Z13.79 - Encounter for other screening for genetic and chromosomal anomalies

• Z13.810 - Encounter for screening for upper gastrointestinal disorder

• Z13.811 - Encounter for screening for lower gastrointestinal disorder

• Z13.818 - Encounter for screening for other digestive system disorders

• Z13.820 - Encounter for screening for osteoporosis

• Z13.828 - Encounter for screening for other musculoskeletal disorder

• Z13.83 - Encounter for screening for respiratory disorder NEC

• Z13.84 - Encounter for screening for dental disorders

• Z13.850 - Encounter for screening for traumatic brain injury

• Z13.858 - Encounter for screening for other nervous system disorders

• Z13.88 - Encounter for screening for disorder due to exposure to contaminants

• Z13.89 - Encounter for screening for other disorder

• Z13.9 - Encounter for screening, unspecified

Genetic carrier (Z14)

• Z14.01 - Asymptomatic hemophilia A carrier

• Z14.02 - Symptomatic hemophilia A carrier

• Z14.1 - Cystic fibrosis carrier

• Z14.8 - Genetic carrier of other disease

Genetic susceptibility to disease (Z15)

• Z15.01 - Genetic susceptibility to malignant neoplasm of breast

• Z15.02 - Genetic susceptibility to malignant neoplasm of ovary

• Z15.03 - Genetic susceptibility to malignant neoplasm of prostate

• Z15.04 - Genetic susceptibility to malignant neoplasm of endometrium

• Z15.09 - Genetic susceptibility to other malignant neoplasm

• Z15.1 - Genetic susceptibility to epilepsy and neurodevelopmental disorders

• Z15.2 - Genetic susceptibility to obesity

• Z15.81 - Genetic susceptibility to multiple endocrine neoplasia [MEN]

• Z15.89 - Genetic susceptibility to other disease

Resistance to antimicrobial drugs (Z16)

• Z16.10 - Resistance to unspecified beta lactam antibiotics

• Z16.11 - Resistance to penicillins

• Z16.12 - Extended spectrum beta lactamase (ESBL) resistance

• Z16.13 - Resistance to carbapenem

• Z16.19 - Resistance to other specified beta lactam antibiotics

• Z16.20 - Resistance to unspecified antibiotic

• Z16.21 - Resistance to vancomycin

• Z16.22 - Resistance to vancomycin related antibiotics

• Z16.23 - Resistance to quinolones and fluoroquinolones

• Z16.24 - Resistance to multiple antibiotics

• Z16.29 - Resistance to other single specified antibiotic

• Z16.30 - Resistance to unspecified antimicrobial drugs

• Z16.31 - Resistance to antiparasitic drug(s)

• Z16.32 - Resistance to antifungal drug(s)

• Z16.33 - Resistance to antiviral drug(s)

• Z16.341 - Resistance to single antimycobacterial drug

• Z16.342 - Resistance to multiple antimycobacterial drugs

• Z16.35 - Resistance to multiple antimicrobial drugs

• Z16.39 - Resistance to other specified antimicrobial drug

Estrogen, and other hormones and factors receptor status (Z17)

• Z17.0 - Estrogen receptor positive status [ER+]

• Z17.1 - Estrogen receptor negative status [ER-]

• Z17.21 - Progesterone receptor positive status

• Z17.22 - Progesterone receptor negative status

• Z17.31 - Human epidermal growth factor receptor 2 positive status

• Z17.32 - Human epidermal growth factor receptor 2 negative status

• Z17.410 - Hormone receptor positive with human epidermal growth factor receptor 2 positive status

• Z17.411 - Hormone receptor positive with human epidermal growth factor receptor 2 negative status

• Z17.420 - Hormone receptor negative with human epidermal growth factor receptor 2 positive status

• Z17.421 - Hormone receptor negative with human epidermal growth factor receptor 2 negative status

Retained foreign body fragments (Z18)

• Z18.01 - Retained depleted uranium fragments

• Z18.09 - Other retained radioactive fragments

• Z18.10 - Retained metal fragments, unspecified

• Z18.11 - Retained magnetic metal fragments

• Z18.12 - Retained nonmagnetic metal fragments

• Z18.2 - Retained plastic fragments

• Z18.31 - Retained animal quills or spines

• Z18.32 - Retained tooth

• Z18.33 - Retained wood fragments

• Z18.39 - Other retained organic fragments

• Z18.81 - Retained glass fragments

• Z18.83 - Retained stone or crystalline fragments

• Z18.89 - Other specified retained foreign body fragments

• Z18.9 - Retained foreign body fragments, unspecified material

Hormone sensitivity malignancy status (Z19)

• Z19.1 - Hormone sensitive malignancy status

• Z19.2 - Hormone resistant malignancy status

Contact with and (suspected) exposure to communicable diseases (Z20)

• Z20.09 - Contact with and (suspected) exposure to other intestinal infectious diseases

• Z20.1 - Contact with and (suspected) exposure to tuberculosis

• Z20.2 - Contact with and (suspected) exposure to infections with a predominantly sexual mode of transmission

• Z20.3 - Contact with and (suspected) exposure to rabies

• Z20.4 - Contact with and (suspected) exposure to rubella

• Z20.7 - Contact with and (suspected) exposure to pediculosis, acariasis and other infestations

• Z20.810 - Contact with and (suspected) exposure to anthrax

• Z20.818 - Contact with and (suspected) exposure to other bacterial communicable diseases

• Z20.821 - Contact with and (suspected) exposure to Zika virus

• Z20.822 - Contact with and (suspected) exposure to COVID-19

• Z20.89 - Contact with and (suspected) exposure to other communicable diseases

• Z20.9 - Contact with and (suspected) exposure to unspecified communicable disease

Carrier of infectious disease (Z22)

• Z22.0 - Carrier of typhoid

• Z22.1 - Carrier of other intestinal infectious diseases

• Z22.2 - Carrier of diphtheria

• Z22.31 - Carrier of bacterial disease due to meningococci

• Z22.321 - Carrier or suspected carrier of Methicillin susceptible Staphylococcus aureus

• Z22.322 - Carrier or suspected carrier of Methicillin resistant Staphylococcus aureus

• Z22.330 - Carrier of Group B streptococcus

• Z22.338 - Carrier of other streptococcus

• Z22.340 - Carrier of carbapenem-resistant Acinetobacter baumannii

• Z22.341 - Carrier of carbapenem-sensitive Acinetobacter baumannii

• Z22.349 - Carrier of Acinetobacter baumannii, unspecified

• Z22.350 - Carrier of carbapenem-resistant Enterobacterales

• Z22.358 - Carrier of other Enterobacterales

• Z22.359 - Carrier of Enterobacterales, unspecified

• Z22.39 - Carrier of other specified bacterial diseases

• Z22.4 - Carrier of infections with a predominantly sexual mode of transmission

• Z22.6 - Carrier of human T-lymphotropic virus type-1 [HTLV-1] infection

• Z22.7 - Latent tuberculosis

• Z22.8 - Carrier of other infectious diseases

• Z22.9 - Carrier of infectious disease, unspecified

Encounter for immunization (Z23)

• Z23 - Encounter for immunization

Immunization not carried out and underimmunization status (Z28)

• Z28.01 - Immunization not carried out because of acute illness of patient

• Z28.02 - Immunization not carried out because of chronic illness or condition of patient

• Z28.03 - Immunization not carried out because of immune compromised state of patient

• Z28.04 - Immunization not carried out because of patient allergy to vaccine or component

• Z28.09 - Immunization not carried out because of other contraindication

• Z28.1 - Immunization not carried out because of patient decision for reasons of belief or group pressure

• Z28.20 - Immunization not carried out because of patient decision for unspecified reason

• Z28.21 - Immunization not carried out because of patient refusal

• Z28.29 - Immunization not carried out because of patient decision for other reason

• Z28.310 - Unvaccinated for COVID-19

• Z28.311 - Partially vaccinated for COVID-19

• Z28.39 - Other underimmunization status

• Z28.81 - Immunization not carried out due to patient having had the disease

• Z28.82 - Immunization not carried out because of caregiver refusal

• Z28.83 - Immunization not carried out due to unavailability of vaccine

• Z28.89 - Immunization not carried out for other reason

• Z28.9 - Immunization not carried out for unspecified reason

Encounter for other prophylactic measures (Z29)

• Z29.11 - Encounter for prophylactic immunotherapy for respiratory syncytial virus (RSV)

• Z29.12 - Encounter for prophylactic antivenin

• Z29.13 - Encounter for prophylactic Rho(D) immune globulin

• Z29.14 - Encounter for prophylactic rabies immune globin

• Z29.3 - Encounter for prophylactic fluoride administration

• Z29.81 - Encounter for HIV pre-exposure prophylaxis

• Z29.89 - Encounter for other specified prophylactic measures

• Z29.9 - Encounter for prophylactic measures, unspecified

Encounter for contraceptive management (Z30)

• Z30.011 - Encounter for initial prescription of contraceptive pills

• Z30.012 - Encounter for prescription of emergency contraception

• Z30.013 - Encounter for initial prescription of injectable contraceptive

• Z30.014 - Encounter for initial prescription of intrauterine contraceptive device

• Z30.015 - Encounter for initial prescription of vaginal ring hormonal contraceptive

• Z30.016 - Encounter for initial prescription of transdermal patch hormonal contraceptive device

• Z30.017 - Encounter for initial prescription of implantable subdermal contraceptive

• Z30.018 - Encounter for initial prescription of other contraceptives

• Z30.019 - Encounter for initial prescription of contraceptives, unspecified

• Z30.02 - Counseling and instruction in natural family planning to avoid pregnancy

• Z30.09 - Encounter for other general counseling and advice on contraception

• Z30.40 - Encounter for surveillance of contraceptives, unspecified

• Z30.41 - Encounter for surveillance of contraceptive pills

• Z30.42 - Encounter for surveillance of injectable contraceptive

• Z30.430 - Encounter for insertion of intrauterine contraceptive device

• Z30.431 - Encounter for routine checking of intrauterine contraceptive device

• Z30.432 - Encounter for removal of intrauterine contraceptive device

• Z30.433 - Encounter for removal and reinsertion of intrauterine contraceptive device

• Z30.44 - Encounter for surveillance of vaginal ring hormonal contraceptive device

• Z30.45 - Encounter for surveillance of transdermal patch hormonal contraceptive device

• Z30.46 - Encounter for surveillance of implantable subdermal contraceptive

• Z30.49 - Encounter for surveillance of other contraceptives

• Z30.8 - Encounter for other contraceptive management

• Z30.9 - Encounter for contraceptive management, unspecified

Encounter for procreative management (Z31)

• Z31.41 - Encounter for fertility testing

• Z31.42 - Aftercare following sterilization reversal

• Z31.430 - Encounter of female for testing for genetic disease carrier status for procreative management

• Z31.438 - Encounter for other genetic testing of female for procreative management

• Z31.440 - Encounter of male for testing for genetic disease carrier status for procreative management

• Z31.441 - Encounter for testing of male partner of patient with recurrent pregnancy loss

• Z31.448 - Encounter for other genetic testing of male for procreative management

• Z31.49 - Encounter for other procreative investigation and testing

• Z31.5 - Encounter for procreative genetic counseling

• Z31.61 - Procreative counseling and advice using natural family planning

• Z31.62 - Encounter for fertility preservation counseling

• Z31.69 - Encounter for other general counseling and advice on procreation

• Z31.7 - Encounter for procreative management and counseling for gestational carrier

• Z31.81 - Encounter for male factor infertility in female patient

• Z31.82 - Encounter for Rh incompatibility status

• Z31.83 - Encounter for assisted reproductive fertility procedure cycle

• Z31.84 - Encounter for fertility preservation procedure

• Z31.89 - Encounter for other procreative management

• Z31.9 - Encounter for procreative management, unspecified

Encounter for pregnancy test and childbirth and childcare instruction (Z32)

• Z32.2 - Encounter for childbirth instruction

• Z32.3 - Encounter for childcare instruction

Pregnant state (Z33)

• Z33.1 - Pregnant state, incidental

• Z33.3 - Pregnant state, gestational carrier

Encounter for supervision of normal pregnancy (Z34)

• Z34.00 - Encounter for supervision of normal first pregnancy, unspecified trimester

• Z34.01 - Encounter for supervision of normal first pregnancy, first trimester

• Z34.02 - Encounter for supervision of normal first pregnancy, second trimester

• Z34.03 - Encounter for supervision of normal first pregnancy, third trimester

• Z34.80 - Encounter for supervision of other normal pregnancy, unspecified trimester

• Z34.81 - Encounter for supervision of other normal pregnancy, first trimester

• Z34.82 - Encounter for supervision of other normal pregnancy, second trimester

• Z34.83 - Encounter for supervision of other normal pregnancy, third trimester

• Z34.90 - Encounter for supervision of normal pregnancy, unspecified, unspecified trimester

• Z34.91 - Encounter for supervision of normal pregnancy, unspecified, first trimester

• Z34.92 - Encounter for supervision of normal pregnancy, unspecified, second trimester

• Z34.93 - Encounter for supervision of normal pregnancy, unspecified, third trimester

Outcome of delivery (Z37)

• Z37.0 - Single live birth

• Z37.1 - Single stillbirth

• Z37.2 - Twins, both liveborn

• Z37.3 - Twins, one liveborn and one stillborn

• Z37.4 - Twins, both stillborn

• Z37.50 - Multiple births, unspecified, all liveborn

• Z37.51 - Triplets, all liveborn

• Z37.52 - Quadruplets, all liveborn

• Z37.53 - Quintuplets, all liveborn

• Z37.54 - Sextuplets, all liveborn

• Z37.59 - Other multiple births, all liveborn

• Z37.60 - Multiple births, unspecified, some liveborn

• Z37.61 - Triplets, some liveborn

• Z37.62 - Quadruplets, some liveborn

• Z37.63 - Quintuplets, some liveborn

• Z37.64 - Sextuplets, some liveborn

• Z37.69 - Other multiple births, some liveborn

• Z37.7 - Other multiple births, all stillborn

• Z37.9 - Outcome of delivery, unspecified

Encounter for maternal postpartum care and examination (Z39)

• Z39.1 - Encounter for care and examination of lactating mother

• Z39.2 - Encounter for routine postpartum follow-up

Weeks of gestation (Z3A)

• Z3A.00 - Weeks of gestation of pregnancy not specified

• Z3A.01 - Less than 8 weeks gestation of pregnancy

• Z3A.08 - 8 weeks gestation of pregnancy

• Z3A.09 - 9 weeks gestation of pregnancy

• Z3A.10 - 10 weeks gestation of pregnancy

• Z3A.11 - 11 weeks gestation of pregnancy

• Z3A.12 - 12 weeks gestation of pregnancy

• Z3A.13 - 13 weeks gestation of pregnancy

• Z3A.14 - 14 weeks gestation of pregnancy

• Z3A.15 - 15 weeks gestation of pregnancy

• Z3A.16 - 16 weeks gestation of pregnancy

• Z3A.17 - 17 weeks gestation of pregnancy

• Z3A.18 - 18 weeks gestation of pregnancy

• Z3A.19 - 19 weeks gestation of pregnancy

• Z3A.20 - 20 weeks gestation of pregnancy

• Z3A.21 - 21 weeks gestation of pregnancy

• Z3A.22 - 22 weeks gestation of pregnancy

• Z3A.23 - 23 weeks gestation of pregnancy

• Z3A.24 - 24 weeks gestation of pregnancy

• Z3A.25 - 25 weeks gestation of pregnancy

• Z3A.26 - 26 weeks gestation of pregnancy

• Z3A.27 - 27 weeks gestation of pregnancy

• Z3A.28 - 28 weeks gestation of pregnancy

• Z3A.29 - 29 weeks gestation of pregnancy

• Z3A.30 - 30 weeks gestation of pregnancy

• Z3A.31 - 31 weeks gestation of pregnancy

• Z3A.32 - 32 weeks gestation of pregnancy

• Z3A.33 - 33 weeks gestation of pregnancy

• Z3A.34 - 34 weeks gestation of pregnancy

• Z3A.35 - 35 weeks gestation of pregnancy

• Z3A.36 - 36 weeks gestation of pregnancy

• Z3A.37 - 37 weeks gestation of pregnancy

• Z3A.38 - 38 weeks gestation of pregnancy

• Z3A.39 - 39 weeks gestation of pregnancy

• Z3A.40 - 40 weeks gestation of pregnancy

• Z3A.41 - 41 weeks gestation of pregnancy

• Z3A.42 - 42 weeks gestation of pregnancy

• Z3A.49 - Greater than 42 weeks gestation of pregnancy

Encounter for prophylactic surgery (Z40)

• Z40.8 - Encounter for other prophylactic surgery

• Z40.9 - Encounter for prophylactic surgery, unspecified

Encounter for procedures for purposes other than remedying health state (Z41)

• Z41.3 - Encounter for ear piercing

• Z41.9 - Encounter for procedure for purposes other than remedying health state, unspecified

Encounter for attention to artificial openings (Z43)

• Z43.9 - Encounter for attention to unspecified artificial opening

Encounter for fitting and adjustment of external prosthetic device (Z44)

• Z44.9 - Encounter for fitting and adjustment of unspecified external prosthetic device

Encounter for adjustment and management of implanted device (Z45)

• Z45.82 - Encounter for adjustment or removal of myringotomy device (stent) (tube)

• Z45.89 - Encounter for adjustment and management of other implanted devices

• Z45.9 - Encounter for adjustment and management of unspecified implanted device

Encounter for fitting and adjustment of other devices (Z46)

• Z46.0 - Encounter for fitting and adjustment of spectacles and contact lenses

• Z46.1 - Encounter for fitting and adjustment of hearing aid

• Z46.4 - Encounter for fitting and adjustment of orthodontic device

• Z46.51 - Encounter for fitting and adjustment of gastric lap band

• Z46.59 - Encounter for fitting and adjustment of other gastrointestinal appliance and device

• Z46.6 - Encounter for fitting and adjustment of urinary device

• Z46.81 - Encounter for fitting and adjustment of insulin pump

• Z46.89 - Encounter for fitting and adjustment of other specified devices

• Z46.9 - Encounter for fitting and adjustment of unspecified device

Encounter for other postprocedural aftercare (Z48)

• Z48.00 - Encounter for change or removal of nonsurgical wound dressing

• Z48.01 - Encounter for change or removal of surgical wound dressing

• Z48.02 - Encounter for removal of sutures

Encounter for care involving renal dialysis (Z49)

• Z49.01 - Encounter for fitting and adjustment of extracorporeal dialysis catheter

• Z49.02 - Encounter for fitting and adjustment of peritoneal dialysis catheter

• Z49.31 - Encounter for adequacy testing for hemodialysis

• Z49.32 - Encounter for adequacy testing for peritoneal dialysis

Encounter for other aftercare and medical care (Z51)

• Z51.6 - Encounter for desensitization to allergens

Donors of organs and tissues (Z52)

• Z52.000 - Unspecified donor, whole blood

• Z52.001 - Unspecified donor, stem cells

• Z52.008 - Unspecified donor, other blood

• Z52.010 - Autologous donor, whole blood

• Z52.011 - Autologous donor, stem cells

• Z52.018 - Autologous donor, other blood

• Z52.090 - Other blood donor, whole blood

• Z52.091 - Other blood donor, stem cells

• Z52.098 - Other blood donor, other blood

• Z52.810 - Egg (Oocyte) donor under age 35, anonymous recipient

• Z52.811 - Egg (Oocyte) donor under age 35, designated recipient

• Z52.812 - Egg (Oocyte) donor age 35 and over, anonymous recipient

• Z52.813 - Egg (Oocyte) donor age 35 and over, designated recipient

• Z52.819 - Egg (Oocyte) donor, unspecified

Persons encountering health services for specific procedures and treatment, not carried out (Z53)

• Z53.01 - Procedure and treatment not carried out due to patient smoking

• Z53.09 - Procedure and treatment not carried out because of other contraindication

• Z53.1 - Procedure and treatment not carried out because of patient's decision for reasons of belief and group pressure

• Z53.20 - Procedure and treatment not carried out because of patient's decision for unspecified reasons

• Z53.21 - Procedure and treatment not carried out due to patient leaving prior to being seen by health care provider

• Z53.29 - Procedure and treatment not carried out because of patient's decision for other reasons

• Z53.31 - Laparoscopic surgical procedure converted to open procedure

• Z53.32 - Thoracoscopic surgical procedure converted to open procedure

• Z53.33 - Arthroscopic surgical procedure converted to open procedure

• Z53.39 - Other specified procedure converted to open procedure

• Z53.8 - Procedure and treatment not carried out for other reasons

• Z53.9 - Procedure and treatment not carried out, unspecified reason

Problems related to education and literacy (Z55)

• Z55.0 - Illiteracy and low-level literacy

• Z55.1 - Schooling unavailable and unattainable

• Z55.2 - Failed school examinations

• Z55.3 - Underachievement in school

• Z55.4 - Educational maladjustment and discord with teachers and classmates

• Z55.5 - Less than a high school diploma

• Z55.6 - Problems related to health literacy

• Z55.8 - Other problems related to education and literacy

• Z55.9 - Problems related to education and literacy, unspecified

Problems related to employment and unemployment (Z56)

• Z56.0 - Unemployment, unspecified

• Z56.1 - Change of job

• Z56.2 - Threat of job loss

• Z56.3 - Stressful work schedule

• Z56.4 - Discord with boss and workmates

• Z56.5 - Uncongenial work environment

• Z56.6 - Other physical and mental strain related to work

• Z56.81 - Sexual harassment on the job

• Z56.82 - Military deployment status

• Z56.89 - Other problems related to employment

• Z56.9 - Unspecified problems related to employment

Occupational exposure to risk factors (Z57)

• Z57.0 - Occupational exposure to noise

• Z57.1 - Occupational exposure to radiation

• Z57.2 - Occupational exposure to dust

• Z57.31 - Occupational exposure to environmental tobacco smoke

• Z57.39 - Occupational exposure to other air contaminants

• Z57.4 - Occupational exposure to toxic agents in agriculture

• Z57.5 - Occupational exposure to toxic agents in other industries

• Z57.6 - Occupational exposure to extreme temperature

• Z57.7 - Occupational exposure to vibration

• Z57.8 - Occupational exposure to other risk factors

• Z57.9 - Occupational exposure to unspecified risk factor

Problems related to physical environment (Z58)

• Z58.6 - Inadequate drinking-water supply

• Z58.81 - Basic services unavailable in physical environment

• Z58.89 - Other problems related to physical environment

Problems related to housing and economic circumstances (Z59)

• Z59.00 - Homelessness unspecified

• Z59.01 - Sheltered homelessness

• Z59.02 - Unsheltered homelessness

• Z59.10 - Inadequate housing, unspecified

• Z59.11 - Inadequate housing environmental temperature

• Z59.12 - Inadequate housing utilities

• Z59.19 - Other inadequate housing

• Z59.2 - Discord with neighbors, lodgers and landlord

• Z59.3 - Problems related to living in residential institution

• Z59.41 - Food insecurity

• Z59.48 - Other specified lack of adequate food

• Z59.5 - Extreme poverty

• Z59.6 - Low income

• Z59.71 - Insufficient health insurance coverage

• Z59.72 - Insufficient welfare support

• Z59.811 - Housing instability, housed, with risk of homelessness

• Z59.812 - Housing instability, housed, homelessness in past 12 months

• Z59.819 - Housing instability, housed unspecified

• Z59.82 - Transportation insecurity

• Z59.86 - Financial insecurity

• Z59.87 - Material hardship due to limited financial resources, not elsewhere classified

• Z59.89 - Other problems related to housing and economic circumstances

• Z59.9 - Problem related to housing and economic circumstances, unspecified

Problems related to social environment (Z60)

• Z60.0 - Problems of adjustment to life-cycle transitions

• Z60.2 - Problems related to living alone

• Z60.3 - Acculturation difficulty

• Z60.4 - Social exclusion and rejection

• Z60.5 - Target of (perceived) adverse discrimination and persecution

• Z60.8 - Other problems related to social environment

• Z60.9 - Problem related to social environment, unspecified

Problems related to upbringing (Z62)

• Z62.0 - Inadequate parental supervision and control

• Z62.1 - Parental overprotection

• Z62.21 - Child in welfare custody

• Z62.22 - Institutional upbringing

• Z62.23 - Child in custody of non-parental relative

• Z62.24 - Child in custody of non-relative guardian

• Z62.29 - Other upbringing away from parents

• Z62.3 - Hostility towards and scapegoating of child

• Z62.6 - Inappropriate (excessive) parental pressure

• Z62.810 - Personal history of physical and sexual abuse in childhood

• Z62.811 - Personal history of psychological abuse in childhood

• Z62.812 - Personal history of neglect in childhood

• Z62.813 - Personal history of forced labor or sexual exploitation in childhood

• Z62.814 - Personal history of child financial abuse

• Z62.815 - Personal history of intimate partner abuse in childhood

• Z62.819 - Personal history of unspecified abuse in childhood

• Z62.820 - Parent-biological child conflict

• Z62.821 - Parent-adopted child conflict

• Z62.822 - Parent-foster child conflict

• Z62.823 - Parent-step child conflict

• Z62.831 - Non-parental relative-child conflict

• Z62.832 - Non-relative guardian-child conflict

• Z62.833 - Group home staff-child conflict

• Z62.890 - Parent-child estrangement NEC

• Z62.891 - Sibling rivalry

• Z62.892 - Runaway [from current living environment]

• Z62.898 - Other specified problems related to upbringing

• Z62.9 - Problem related to upbringing, unspecified

Other problems related to primary support group, including family circumstances (Z63)

• Z63.0 - Problems in relationship with spouse or partner

• Z63.1 - Problems in relationship with in-laws

• Z63.31 - Absence of family member due to military deployment

• Z63.32 - Other absence of family member

• Z63.4 - Disappearance and death of family member

• Z63.5 - Disruption of family by separation and divorce

• Z63.6 - Dependent relative needing care at home

• Z63.71 - Stress on family due to return of family member from military deployment

• Z63.72 - Alcoholism and drug addiction in family

• Z63.79 - Other stressful life events affecting family and household

• Z63.8 - Other specified problems related to primary support group

• Z63.9 - Problem related to primary support group, unspecified

Problems related to certain psychosocial circumstances (Z64)

• Z64.0 - Problems related to unwanted pregnancy

• Z64.1 - Problems related to multiparity

• Z64.4 - Discord with counselors

Problems related to other psychosocial circumstances (Z65)

• Z65.0 - Conviction in civil and criminal proceedings without imprisonment

• Z65.1 - Imprisonment and other incarceration

• Z65.2 - Problems related to release from prison

• Z65.3 - Problems related to other legal circumstances

• Z65.4 - Victim of crime and terrorism

• Z65.5 - Exposure to disaster, war and other hostilities

• Z65.8 - Other specified problems related to psychosocial circumstances

• Z65.9 - Problem related to unspecified psychosocial circumstances

Do not resuscitate (Z66)

• Z66 - Do not resuscitate

Blood type (Z67)

• Z67.10 - Type A blood, Rh positive

• Z67.11 - Type A blood, Rh negative

• Z67.20 - Type B blood, Rh positive

• Z67.21 - Type B blood, Rh negative

• Z67.30 - Type AB blood, Rh positive

• Z67.31 - Type AB blood, Rh negative

• Z67.40 - Type O blood, Rh positive

• Z67.41 - Type O blood, Rh negative

• Z67.90 - Unspecified blood type, Rh positive

• Z67.91 - Unspecified blood type, Rh negative

• Z67.A1 - Duffy null

• Z67.A2 - Duffy a positive

• Z67.A3 - Duffy b positive

• Z67.A4 - Duffy a and b positive

Body mass index [BMI] (Z68)

• Z68.1 - Body mass index [BMI] 19.9 or less, adult

• Z68.20 - Body mass index [BMI] 20.0-20.9, adult

• Z68.21 - Body mass index [BMI] 21.0-21.9, adult

• Z68.22 - Body mass index [BMI] 22.0-22.9, adult

• Z68.23 - Body mass index [BMI] 23.0-23.9, adult

• Z68.24 - Body mass index [BMI] 24.0-24.9, adult

• Z68.25 - Body mass index [BMI] 25.0-25.9, adult

• Z68.26 - Body mass index [BMI] 26.0-26.9, adult

• Z68.27 - Body mass index [BMI] 27.0-27.9, adult

• Z68.28 - Body mass index [BMI] 28.0-28.9, adult

• Z68.29 - Body mass index [BMI] 29.0-29.9, adult

• Z68.30 - Body mass index [BMI] 30.0-30.9, adult

• Z68.31 - Body mass index [BMI] 31.0-31.9, adult

• Z68.32 - Body mass index [BMI] 32.0-32.9, adult

• Z68.33 - Body mass index [BMI] 33.0-33.9, adult

• Z68.34 - Body mass index [BMI] 34.0-34.9, adult

• Z68.35 - Body mass index [BMI] 35.0-35.9, adult

• Z68.36 - Body mass index [BMI] 36.0-36.9, adult

• Z68.37 - Body mass index [BMI] 37.0-37.9, adult

• Z68.38 - Body mass index [BMI] 38.0-38.9, adult

• Z68.39 - Body mass index [BMI] 39.0-39.9, adult

• Z68.41 - Body mass index [BMI] 40.0-44.9, adult

• Z68.42 - Body mass index [BMI] 45.0-49.9, adult

• Z68.43 - Body mass index [BMI] 50.0-59.9, adult

• Z68.44 - Body mass index [BMI] 60.0-69.9, adult

• Z68.45 - Body mass index [BMI] 70 or greater, adult

• Z68.51 - Body mass index [BMI] pediatric, less than 5th percentile for age

• Z68.52 - Body mass index [BMI] pediatric, 5th percentile to less than 85th percentile for age

• Z68.53 - Body mass index [BMI] pediatric, 85th percentile to less than 95th percentile for age

• Z68.54 - Body mass index [BMI] pediatric, 95th percentile for age to less than 120% of the 95th percentile for age

• Z68.55 - Body mass index [BMI] pediatric, 120% of the 95th percentile for age to less than 140% of the 95th percentile for age

• Z68.56 - Body mass index [BMI] pediatric, greater than or equal to 140% of the 95th percentile for age

Encounter for mental health services for victim and perpetrator of abuse (Z69)

• Z69.011 - Encounter for mental health services for perpetrator of parental child abuse

• Z69.021 - Encounter for mental health services for perpetrator of non-parental child abuse

• Z69.11 - Encounter for mental health services for victim of spousal or partner abuse

• Z69.12 - Encounter for mental health services for perpetrator of spousal or partner abuse

• Z69.81 - Encounter for mental health services for victim of other abuse

• Z69.82 - Encounter for mental health services for perpetrator of other abuse

Counseling related to sexual attitude, behavior and orientation (Z70)

• Z70.0 - Counseling related to sexual attitude

• Z70.1 - Counseling related to patient's sexual behavior and orientation

• Z70.2 - Counseling related to sexual behavior and orientation of third party

• Z70.3 - Counseling related to combined concerns regarding sexual attitude, behavior and orientation

• Z70.8 - Other sex counseling

• Z70.9 - Sex counseling, unspecified

Persons encountering health services for other counseling and medical advice, not elsewhere classified (Z71)

• Z71.0 - Person encountering health services to consult on behalf of another person

• Z71.1 - Person with feared health complaint in whom no diagnosis is made

• Z71.2 - Person consulting for explanation of examination or test findings

• Z71.3 - Dietary counseling and surveillance

• Z71.41 - Alcohol abuse counseling and surveillance of alcoholic

• Z71.42 - Counseling for family member of alcoholic

• Z71.51 - Drug abuse counseling and surveillance of drug abuser

• Z71.52 - Counseling for family member of drug abuser

• Z71.6 - Tobacco abuse counseling

• Z71.7 - Human immunodeficiency virus [HIV] counseling

• Z71.81 - Spiritual or religious counseling

• Z71.82 - Exercise counseling

• Z71.84 - Encounter for health counseling related to travel

• Z71.85 - Encounter for immunization safety counseling

• Z71.87 - Encounter for pediatric-to-adult transition counseling

• Z71.88 - Encounter for counseling for socioeconomic factors

• Z71.89 - Other specified counseling

• Z71.9 - Counseling, unspecified

Problems related to lifestyle (Z72)

• Z72.0 - Tobacco use

• Z72.3 - Lack of physical exercise

• Z72.4 - Inappropriate diet and eating habits

• Z72.51 - High risk heterosexual behavior

• Z72.52 - High risk homosexual behavior

• Z72.53 - High risk bisexual behavior

• Z72.6 - Gambling and betting

• Z72.821 - Inadequate sleep hygiene

• Z72.823 - Risk of suffocation (smothering) under another while sleeping

• Z72.89 - Other problems related to lifestyle

• Z72.9 - Problem related to lifestyle, unspecified

Problems related to life management difficulty (Z73)

• Z73.0 - Burn-out

• Z73.1 - Type A behavior pattern

• Z73.2 - Lack of relaxation and leisure

• Z73.3 - Stress, not elsewhere classified

• Z73.4 - Inadequate social skills, not elsewhere classified

• Z73.5 - Social role conflict, not elsewhere classified

• Z73.6 - Limitation of activities due to disability

• Z73.810 - Behavioral insomnia of childhood, sleep-onset association type

• Z73.811 - Behavioral insomnia of childhood, limit setting type

• Z73.812 - Behavioral insomnia of childhood, combined type

• Z73.819 - Behavioral insomnia of childhood, unspecified type

• Z73.82 - Dual sensory impairment

• Z73.89 - Other problems related to life management difficulty

• Z73.9 - Problem related to life management difficulty, unspecified

Problems related to care provider dependency (Z74)

• Z74.01 - Bed confinement status

• Z74.09 - Other reduced mobility

• Z74.1 - Need for assistance with personal care

• Z74.2 - Need for assistance at home and no other household member able to render care

• Z74.3 - Need for continuous supervision

• Z74.8 - Other problems related to care provider dependency

• Z74.9 - Problem related to care provider dependency, unspecified

Problems related to medical facilities and other health care (Z75)

• Z75.0 - Medical services not available in home

• Z75.1 - Person awaiting admission to adequate facility elsewhere

• Z75.2 - Other waiting period for investigation and treatment

• Z75.3 - Unavailability and inaccessibility of health-care facilities

• Z75.4 - Unavailability and inaccessibility of other helping agencies

• Z75.5 - Holiday relief care

• Z75.8 - Other problems related to medical facilities and other health care

• Z75.9 - Unspecified problem related to medical facilities and other health care

Persons encountering health services in other circumstances (Z76)

• Z76.0 - Encounter for issue of repeat prescription

• Z76.2 - Encounter for health supervision and care of other healthy infant and child

• Z76.81 - Expectant parent(s) prebirth pediatrician visit

• Z76.82 - Awaiting organ transplant status

• Z76.89 - Persons encountering health services in other specified circumstances

Other contact with and (suspected) exposures hazardous to health (Z77)

• Z77.010 - Contact with and (suspected) exposure to arsenic

• Z77.011 - Contact with and (suspected) exposure to lead

• Z77.012 - Contact with and (suspected) exposure to uranium

• Z77.018 - Contact with and (suspected) exposure to other hazardous metals

• Z77.020 - Contact with and (suspected) exposure to aromatic amines

• Z77.021 - Contact with and (suspected) exposure to benzene

• Z77.028 - Contact with and (suspected) exposure to other hazardous aromatic compounds

• Z77.090 - Contact with and (suspected) exposure to asbestos

• Z77.098 - Contact with and (suspected) exposure to other hazardous, chiefly nonmedicinal, chemicals

• Z77.110 - Contact with and (suspected) exposure to air pollution

• Z77.111 - Contact with and (suspected) exposure to water pollution

• Z77.112 - Contact with and (suspected) exposure to soil pollution

• Z77.118 - Contact with and (suspected) exposure to other environmental pollution

• Z77.120 - Contact with and (suspected) exposure to mold (toxic)

• Z77.121 - Contact with and (suspected) exposure to harmful algae and algae toxins

• Z77.122 - Contact with and (suspected) exposure to noise

• Z77.123 - Contact with and (suspected) exposure to radon and other naturally occurring radiation

• Z77.128 - Contact with and (suspected) exposure to other hazards in the physical environment

• Z77.21 - Contact with and (suspected) exposure to potentially hazardous body fluids

• Z77.22 - Contact with and (suspected) exposure to environmental tobacco smoke (acute) (chronic)

• Z77.29 - Contact with and (suspected) exposure to other hazardous substances

• Z77.9 - Other contact with and (suspected) exposures hazardous to health

Other specified health status (Z78)

• Z78.0 - Asymptomatic menopausal state

• Z78.1 - Physical restraint status

• Z78.9 - Other specified health status

Long term (current) drug therapy (Z79)

• Z79.02 - Long term (current) use of antithrombotics/antiplatelets

• Z79.1 - Long term (current) use of non-steroidal anti-inflammatories (NSAID)

• Z79.2 - Long term (current) use of antibiotics

• Z79.51 - Long term (current) use of inhaled steroids

• Z79.52 - Long term (current) use of systemic steroids

• Z79.60 - Long term (current) use of unspecified immunomodulators and immunosuppressants

• Z79.61 - Long term (current) use of immunomodulator

• Z79.620 - Long term (current) use of immunosuppressive biologic

• Z79.621 - Long term (current) use of calcineurin inhibitor

• Z79.622 - Long term (current) use of Janus kinase inhibitor

• Z79.623 - Long term (current) use of mammalian target of rapamycin (mTOR) inhibitor

• Z79.624 - Long term (current) use of inhibitors of nucleotide synthesis

• Z79.630 - Long term (current) use of alkylating agent

• Z79.631 - Long term (current) use of antimetabolite agent

• Z79.632 - Long term (current) use of antitumor antibiotic

• Z79.633 - Long term (current) use of mitotic inhibitor

• Z79.634 - Long term (current) use of topoisomerase inhibitor

• Z79.64 - Long term (current) use of myelosuppressive agent

• Z79.69 - Long term (current) use of other immunomodulators and immunosuppressants

• Z79.810 - Long term (current) use of selective estrogen receptor modulators (SERMs)

• Z79.811 - Long term (current) use of aromatase inhibitors

• Z79.818 - Long term (current) use of other agents affecting estrogen receptors and estrogen levels

• Z79.83 - Long term (current) use of bisphosphonates

• Z79.84 - Long term (current) use of oral hypoglycemic drugs

• Z79.85 - Long-term (current) use of injectable non-insulin antidiabetic drugs

• Z79.890 - Hormone replacement therapy

Family history of primary malignant neoplasm (Z80)

• Z80.0 - Family history of malignant neoplasm of digestive organs

• Z80.1 - Family history of malignant neoplasm of trachea, bronchus and lung

• Z80.2 - Family history of malignant neoplasm of other respiratory and intrathoracic organs

• Z80.3 - Family history of malignant neoplasm of breast

• Z80.41 - Family history of malignant neoplasm of ovary

• Z80.42 - Family history of malignant neoplasm of prostate

• Z80.43 - Family history of malignant neoplasm of testis

• Z80.49 - Family history of malignant neoplasm of other genital organs

• Z80.51 - Family history of malignant neoplasm of kidney

• Z80.52 - Family history of malignant neoplasm of bladder

• Z80.59 - Family history of malignant neoplasm of other urinary tract organ

• Z80.6 - Family history of leukemia

• Z80.7 - Family history of other malignant neoplasms of lymphoid, hematopoietic and related tissues

• Z80.8 - Family history of malignant neoplasm of other organs or systems

• Z80.9 - Family history of malignant neoplasm, unspecified

Family history of mental and behavioral disorders (Z81)

• Z81.0 - Family history of intellectual disabilities

• Z81.1 - Family history of alcohol abuse and dependence

• Z81.2 - Family history of tobacco abuse and dependence

• Z81.3 - Family history of other psychoactive substance abuse and dependence

• Z81.4 - Family history of other substance abuse and dependence

• Z81.8 - Family history of other mental and behavioral disorders

Family history of certain disabilities and chronic diseases (leading to disablement) (Z82)

• Z82.0 - Family history of epilepsy and other diseases of the nervous system

• Z82.1 - Family history of blindness and visual loss

• Z82.2 - Family history of deafness and hearing loss

• Z82.3 - Family history of stroke

• Z82.41 - Family history of sudden cardiac death

• Z82.49 - Family history of ischemic heart disease and other diseases of the circulatory system

• Z82.5 - Family history of asthma and other chronic lower respiratory diseases

• Z82.61 - Family history of arthritis

• Z82.62 - Family history of osteoporosis

• Z82.69 - Family history of other diseases of the musculoskeletal system and connective tissue

• Z82.71 - Family history of polycystic kidney

• Z82.79 - Family history of other congenital malformations, deformations and chromosomal abnormalities

• Z82.8 - Family history of other disabilities and chronic diseases leading to disablement, not elsewhere classified

Family history of other specific disorders (Z83)

• Z83.0 - Family history of human immunodeficiency virus [HIV] disease

• Z83.1 - Family history of other infectious and parasitic diseases

• Z83.2 - Family history of diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism

• Z83.3 - Family history of diabetes mellitus

• Z83.41 - Family history of multiple endocrine neoplasia [MEN] syndrome

• Z83.42 - Family history of familial hypercholesterolemia

• Z83.430 - Family history of elevated lipoprotein(a)

• Z83.438 - Family history of other disorder of lipoprotein metabolism and other lipidemia

• Z83.49 - Family history of other endocrine, nutritional and metabolic diseases

• Z83.511 - Family history of glaucoma

• Z83.518 - Family history of other specified eye disorder

• Z83.52 - Family history of ear disorders

• Z83.6 - Family history of other diseases of the respiratory system

• Z83.710 - Family history of adenomatous and serrated polyps

• Z83.711 - Family history of hyperplastic colon polyps

• Z83.718 - Other family history of colon polyps

• Z83.719 - Family history of colon polyps, unspecified

• Z83.72 - Family history of familial adenomatous polyposis

• Z83.79 - Family history of other diseases of the digestive system

Family history of other conditions (Z84)

• Z84.0 - Family history of diseases of the skin and subcutaneous tissue

• Z84.1 - Family history of disorders of kidney and ureter

• Z84.2 - Family history of other diseases of the genitourinary system

• Z84.3 - Family history of consanguinity

• Z84.81 - Family history of carrier of genetic disease

• Z84.82 - Family history of sudden infant death syndrome

• Z84.89 - Family history of other specified conditions

Personal history of malignant neoplasm (Z85)

• Z85.00 - Personal history of malignant neoplasm of unspecified digestive organ

• Z85.01 - Personal history of malignant neoplasm of esophagus

• Z85.020 - Personal history of malignant carcinoid tumor of stomach

• Z85.028 - Personal history of other malignant neoplasm of stomach

• Z85.030 - Personal history of malignant carcinoid tumor of large intestine

• Z85.038 - Personal history of other malignant neoplasm of large intestine

• Z85.040 - Personal history of malignant carcinoid tumor of rectum

• Z85.048 - Personal history of other malignant neoplasm of rectum, rectosigmoid junction, and anus

• Z85.05 - Personal history of malignant neoplasm of liver

• Z85.060 - Personal history of malignant carcinoid tumor of small intestine

• Z85.068 - Personal history of other malignant neoplasm of small intestine

• Z85.07 - Personal history of malignant neoplasm of pancreas

• Z85.09 - Personal history of malignant neoplasm of other digestive organs

• Z85.110 - Personal history of malignant carcinoid tumor of bronchus and lung

• Z85.118 - Personal history of other malignant neoplasm of bronchus and lung

• Z85.12 - Personal history of malignant neoplasm of trachea

• Z85.20 - Personal history of malignant neoplasm of unspecified respiratory organ

• Z85.21 - Personal history of malignant neoplasm of larynx

• Z85.22 - Personal history of malignant neoplasm of nasal cavities, middle ear, and accessory sinuses

• Z85.230 - Personal history of malignant carcinoid tumor of thymus

• Z85.238 - Personal history of other malignant neoplasm of thymus

• Z85.29 - Personal history of malignant neoplasm of other respiratory and intrathoracic organs

• Z85.3 - Personal history of malignant neoplasm of breast

• Z85.40 - Personal history of malignant neoplasm of unspecified female genital organ

• Z85.41 - Personal history of malignant neoplasm of cervix uteri

• Z85.42 - Personal history of malignant neoplasm of other parts of uterus

• Z85.43 - Personal history of malignant neoplasm of ovary

• Z85.44 - Personal history of malignant neoplasm of other female genital organs

• Z85.45 - Personal history of malignant neoplasm of unspecified male genital organ

• Z85.46 - Personal history of malignant neoplasm of prostate

• Z85.47 - Personal history of malignant neoplasm of testis

• Z85.48 - Personal history of malignant neoplasm of epididymis

• Z85.49 - Personal history of malignant neoplasm of other male genital organs

• Z85.50 - Personal history of malignant neoplasm of unspecified urinary tract organ

• Z85.51 - Personal history of malignant neoplasm of bladder

• Z85.520 - Personal history of malignant carcinoid tumor of kidney

• Z85.528 - Personal history of other malignant neoplasm of kidney

• Z85.53 - Personal history of malignant neoplasm of renal pelvis

• Z85.54 - Personal history of malignant neoplasm of ureter

• Z85.59 - Personal history of malignant neoplasm of other urinary tract organ

• Z85.6 - Personal history of leukemia

• Z85.71 - Personal history of Hodgkin lymphoma

• Z85.72 - Personal history of non-Hodgkin lymphomas

• Z85.79 - Personal history of other malignant neoplasms of lymphoid, hematopoietic and related tissues

• Z85.810 - Personal history of malignant neoplasm of tongue

• Z85.818 - Personal history of malignant neoplasm of other sites of lip, oral cavity, and pharynx

• Z85.819 - Personal history of malignant neoplasm of unspecified site of lip, oral cavity, and pharynx

• Z85.820 - Personal history of malignant melanoma of skin

• Z85.821 - Personal history of Merkel cell carcinoma

• Z85.828 - Personal history of other malignant neoplasm of skin

• Z85.830 - Personal history of malignant neoplasm of bone

• Z85.831 - Personal history of malignant neoplasm of soft tissue

• Z85.840 - Personal history of malignant neoplasm of eye

• Z85.841 - Personal history of malignant neoplasm of brain

• Z85.848 - Personal history of malignant neoplasm of other parts of nervous tissue

• Z85.850 - Personal history of malignant neoplasm of thyroid

• Z85.858 - Personal history of malignant neoplasm of other endocrine glands

• Z85.89 - Personal history of malignant neoplasm of other organs and systems

• Z85.9 - Personal history of malignant neoplasm, unspecified

Personal history of certain other diseases (Z86)

• Z86.000 - Personal history of in-situ neoplasm of breast

• Z86.001 - Personal history of in-situ neoplasm of cervix uteri

• Z86.002 - Personal history of in-situ neoplasm of other and unspecified genital organs

• Z86.003 - Personal history of in-situ neoplasm of oral cavity, esophagus and stomach

• Z86.004 - Personal history of in-situ neoplasm of other and unspecified digestive organs

• Z86.005 - Personal history of in-situ neoplasm of middle ear and respiratory system

• Z86.006 - Personal history of melanoma in-situ

• Z86.007 - Personal history of in-situ neoplasm of skin

• Z86.008 - Personal history of in-situ neoplasm of other site

• Z86.0100 - Personal history of colon polyps, unspecified

• Z86.0101 - Personal history of adenomatous and serrated colon polyps

• Z86.0102 - Personal history of hyperplastic colon polyps

• Z86.0109 - Personal history of other colon polyps

• Z86.011 - Personal history of benign neoplasm of the brain

• Z86.012 - Personal history of benign carcinoid tumor

• Z86.018 - Personal history of other benign neoplasm

• Z86.03 - Personal history of neoplasm of uncertain behavior

• Z86.11 - Personal history of tuberculosis

• Z86.12 - Personal history of poliomyelitis

• Z86.13 - Personal history of malaria

• Z86.14 - Personal history of Methicillin resistant Staphylococcus aureus infection

• Z86.15 - Personal history of latent tuberculosis infection

• Z86.16 - Personal history of COVID-19

• Z86.19 - Personal history of other infectious and parasitic diseases

• Z86.2 - Personal history of diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism

• Z86.31 - Personal history of diabetic foot ulcer

• Z86.32 - Personal history of gestational diabetes

• Z86.39 - Personal history of other endocrine, nutritional and metabolic disease

• Z86.51 - Personal history of combat and operational stress reaction

• Z86.59 - Personal history of other mental and behavioral disorders

• Z86.61 - Personal history of infections of the central nervous system

• Z86.69 - Personal history of other diseases of the nervous system and sense organs

• Z86.711 - Personal history of pulmonary embolism

• Z86.718 - Personal history of other venous thrombosis and embolism

• Z86.72 - Personal history of thrombophlebitis

• Z86.73 - Personal history of transient ischemic attack (TIA), and cerebral infarction without residual deficits

• Z86.74 - Personal history of sudden cardiac arrest

• Z86.79 - Personal history of other diseases of the circulatory system

Personal history of other diseases and conditions (Z87)

• Z87.01 - Personal history of pneumonia (recurrent)

• Z87.09 - Personal history of other diseases of the respiratory system

• Z87.11 - Personal history of peptic ulcer disease

• Z87.19 - Personal history of other diseases of the digestive system

• Z87.2 - Personal history of diseases of the skin and subcutaneous tissue

• Z87.310 - Personal history of (healed) osteoporosis fracture

• Z87.311 - Personal history of (healed) other pathological fracture

• Z87.312 - Personal history of (healed) stress fracture

• Z87.39 - Personal history of other diseases of the musculoskeletal system and connective tissue

• Z87.410 - Personal history of cervical dysplasia

• Z87.411 - Personal history of vaginal dysplasia

• Z87.412 - Personal history of vulvar dysplasia

• Z87.42 - Personal history of other diseases of the female genital tract

• Z87.430 - Personal history of prostatic dysplasia

• Z87.438 - Personal history of other diseases of male genital organs

• Z87.440 - Personal history of urinary (tract) infections

• Z87.441 - Personal history of nephrotic syndrome

• Z87.442 - Personal history of urinary calculi

• Z87.448 - Personal history of other diseases of urinary system

• Z87.51 - Personal history of pre-term labor

• Z87.59 - Personal history of other complications of pregnancy, childbirth and the puerperium

• Z87.61 - Personal history of (corrected) necrotizing enterocolitis of newborn

• Z87.68 - Personal history of other (corrected) conditions arising in the perinatal period

• Z87.710 - Personal history of (corrected) hypospadias

• Z87.718 - Personal history of other specified (corrected) congenital malformations of genitourinary system

• Z87.720 - Personal history of (corrected) congenital malformations of eye

• Z87.721 - Personal history of (corrected) congenital malformations of ear

• Z87.728 - Personal history of other specified (corrected) congenital malformations of nervous system and sense organs

• Z87.730 - Personal history of (corrected) cleft lip and palate

• Z87.731 - Personal history of (corrected) tracheoesophageal fistula or atresia

• Z87.732 - Personal history of (corrected) persistent cloaca or cloacal malformations

• Z87.738 - Personal history of other specified (corrected) congenital malformations of digestive system

• Z87.74 - Personal history of (corrected) congenital malformations of heart and circulatory system

• Z87.75 - Personal history of (corrected) congenital malformations of respiratory system

• Z87.760 - Personal history of (corrected) congenital diaphragmatic hernia or other congenital diaphragm malformations

• Z87.761 - Personal history of (corrected) gastroschisis

• Z87.762 - Personal history of (corrected) prune belly malformation

• Z87.763 - Personal history of other (corrected) congenital abdominal wall malformations

• Z87.768 - Personal history of other specified (corrected) congenital malformations of integument, limbs and musculoskeletal system

• Z87.790 - Personal history of (corrected) congenital malformations of face and neck

• Z87.798 - Personal history of other (corrected) congenital malformations

• Z87.81 - Personal history of (healed) traumatic fracture

• Z87.820 - Personal history of traumatic brain injury

• Z87.821 - Personal history of retained foreign body fully removed

• Z87.828 - Personal history of other (healed) physical injury and trauma

• Z87.891 - Personal history of nicotine dependence

• Z87.892 - Personal history of anaphylaxis

• Z87.898 - Personal history of other specified conditions

Allergy status to drugs, medicaments and biological substances (Z88)

• Z88.0 - Allergy status to penicillin

• Z88.1 - Allergy status to other antibiotic agents

• Z88.2 - Allergy status to sulfonamides

• Z88.3 - Allergy status to other anti-infective agents

• Z88.4 - Allergy status to anesthetic agent

• Z88.5 - Allergy status to narcotic agent

• Z88.6 - Allergy status to analgesic agent

• Z88.7 - Allergy status to serum and vaccine

• Z88.8 - Allergy status to other drugs, medicaments and biological substances

• Z88.9 - Allergy status to unspecified drugs, medicaments and biological substances

Acquired absence of limb (Z89)

• Z89.011 - Acquired absence of right thumb

• Z89.012 - Acquired absence of left thumb

• Z89.019 - Acquired absence of unspecified thumb

• Z89.021 - Acquired absence of right finger(s)

• Z89.022 - Acquired absence of left finger(s)

• Z89.029 - Acquired absence of unspecified finger(s)

• Z89.111 - Acquired absence of right hand

• Z89.112 - Acquired absence of left hand

• Z89.119 - Acquired absence of unspecified hand

• Z89.121 - Acquired absence of right wrist

• Z89.122 - Acquired absence of left wrist

• Z89.129 - Acquired absence of unspecified wrist

• Z89.201 - Acquired absence of right upper limb, unspecified level

• Z89.202 - Acquired absence of left upper limb, unspecified level

• Z89.209 - Acquired absence of unspecified upper limb, unspecified level

• Z89.211 - Acquired absence of right upper limb below elbow

• Z89.212 - Acquired absence of left upper limb below elbow

• Z89.219 - Acquired absence of unspecified upper limb below elbow

• Z89.221 - Acquired absence of right upper limb above elbow

• Z89.222 - Acquired absence of left upper limb above elbow

• Z89.229 - Acquired absence of unspecified upper limb above elbow

• Z89.231 - Acquired absence of right shoulder

• Z89.232 - Acquired absence of left shoulder

• Z89.239 - Acquired absence of unspecified shoulder

• Z89.411 - Acquired absence of right great toe

• Z89.412 - Acquired absence of left great toe

• Z89.419 - Acquired absence of unspecified great toe

• Z89.421 - Acquired absence of other right toe(s)

• Z89.422 - Acquired absence of other left toe(s)

• Z89.429 - Acquired absence of other toe(s), unspecified side

• Z89.431 - Acquired absence of right foot

• Z89.432 - Acquired absence of left foot

• Z89.439 - Acquired absence of unspecified foot

• Z89.441 - Acquired absence of right ankle

• Z89.442 - Acquired absence of left ankle

• Z89.449 - Acquired absence of unspecified ankle

• Z89.511 - Acquired absence of right leg below knee

• Z89.512 - Acquired absence of left leg below knee

• Z89.519 - Acquired absence of unspecified leg below knee

• Z89.521 - Acquired absence of right knee

• Z89.522 - Acquired absence of left knee

• Z89.529 - Acquired absence of unspecified knee

• Z89.611 - Acquired absence of right leg above knee

• Z89.612 - Acquired absence of left leg above knee

• Z89.619 - Acquired absence of unspecified leg above knee

• Z89.621 - Acquired absence of right hip joint

• Z89.622 - Acquired absence of left hip joint

• Z89.629 - Acquired absence of unspecified hip joint

• Z89.9 - Acquired absence of limb, unspecified

Acquired absence of organs, not elsewhere classified (Z90)

• Z90.01 - Acquired absence of eye

• Z90.02 - Acquired absence of larynx

• Z90.09 - Acquired absence of other part of head and neck

• Z90.2 - Acquired absence of lung [part of]

• Z90.3 - Acquired absence of stomach [part of]

• Z90.410 - Acquired total absence of pancreas

• Z90.411 - Acquired partial absence of pancreas

• Z90.49 - Acquired absence of other specified parts of digestive tract

• Z90.5 - Acquired absence of kidney

• Z90.6 - Acquired absence of other parts of urinary tract

• Z90.710 - Acquired absence of both cervix and uterus

• Z90.711 - Acquired absence of uterus with remaining cervical stump

• Z90.712 - Acquired absence of cervix with remaining uterus

• Z90.721 - Acquired absence of ovaries, unilateral

• Z90.722 - Acquired absence of ovaries, bilateral

• Z90.79 - Acquired absence of other genital organ(s)

• Z90.81 - Acquired absence of spleen

• Z90.89 - Acquired absence of other organs

Personal risk factors, not elsewhere classified (Z91)